Podcasts about Mayo Clinic

Growing up with a narcissistic father, a woman learns to play small, but one night when an unknown masked man enters her room, she faces the worst night of her life, and emerges on the other side with a new found ferocity. Today's episode featured Danielle Leukam. You can learn more about Danielle on her website, danielleleukam.com. And you can find her on Instagram @danielleukam, as well as Twitter and Facebook. You can also learn more about her story in her two memoirs, Four Pounds of Pressure: A Memoir of Rape, Survival, and Taking Back My Power https://amzn.to/3QHxMJW and Another Four Pounds of Pressure: Case Files, Statements, & a Survivor's Redemption https://amzn.to/49I0umr, and lastly, you can check out her novella The First Sister: A Dangerous Bloodline, https://amzn.to/3TjLaXq, as well as the two children's books she's authored. Danielle now works full-time at the Mayo Clinic. She is passionate about public speaking, writing, and advocating against sexual violence. And she is also the president and founder of a non-profit organization called WISH: We Inspire Survivor Healing. Learn more about WISH on their website WeInspireSurvivorHealing.com.ProducersWhit Missildine, Andrew Waits, Aviva LipkowitzContent/Trigger Warningsrape, violent assault, child endangerment, gun violence, alcoholism, explicit language. Social MediaInstagram: @actuallyhappeningFacebook: This Is Actually Happening Discussion GroupWebsite: thisisactuallyhappening.com Substack - The End of the Knownwhitmissildine.substack.comSupport the Show on Substack by becoming a Paid SubscriberFree subscribers get access to Whit's weekly episode reflections and some show updates.Paid subscribers get access to AMAs with the team, follow up interviews with past guests, frequently asked questions, deeper insights into the creative process of the show and live events. A paid Substack subscription is also the best way to support the show. You can also support on Patreon patreon.com/happeningWebsite for Whit Missildinewhitmissildine.comWebsite for Andrew Waitsandrdewwaits.comWebsite for Aviva Lipkowitzavivalipkowitz.comSubscribe on Audible to Listen Ad-FreeAudible subscribers can listen to all episodes of THIS IS ACTUALLY HAPPENING ad-free right now. Join Audible today by downloading the Audible app or visit Audible.com.Shop at the StoreFind This Is Actually Happening branded t-shirts, posters, stickers and more from the shop:thisisactuallyhappening.com/shop TranscriptsFull transcripts of each episode are now available on the website:thisisactuallyhappening.com MusicIntro Music:"Sleep Paralysis" – Scott VelasquezMusic Bed:“Re-Entry” – Lee Rosevere ServicesIf you or someone you know is struggling with the effects of trauma or mental illness, please refer to the following resources:National Suicide & Crisis Lifeline: Text or Call 988National Alliance on Mental Illness (NAMI): 1-800-950-6264National Sexual Assault Hotline (RAINN): 1-800-656-HOPE (4673)See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Mike Staver is a Speaker, founder of The Staver Group, and an executive coach with years of work with clients include the Mayo Clinic, Allstate, FedEx and various real estate groups. Mike holds degrees in business administration and counseling psychology. His books Leadership Isn't for Cowards, gave leaders a framework for making the difficult calls their roles require. His latest book, Navigating Crazy, is about how to live and work sanely, in an insane world.   0.00:    Intro and Mike's background 3.00:    Impact of "The Road Less Travelled" by M Scott Peck 12.00:  Money, Happiness and Values 22.00:  Asset Inflation and the rising cost of living 27.00:  Impact on AI business 35.00:  The importance of Freedom and not being in a prison of "shoulds" 41.00:  How to be a good Leader 47.00:  Why it sucks to be "Resilient" 52.00:  How to overcome "Burnout" 54.00:  Importance of being authentic to yourself Mike's Website: https://mikestaver.com/finishing-ideas/ Mike's Latest Book: "Navigating Crazy: How to Live and Work Sanely in an Insane World"   Until next time, love and good vibes.   Podcast Website: https://enterthelionheart.com/ Check out the latest episode here: Apple Podcast: https://podcasts.apple.com/us/podcast/enter-the-lionheart/id1554904704   Spotify: https://open.spotify.com/show/4tD7VvMUvnOgChoNYShbcI

Blood Cancer Talks — Show NotesEpisode: Best of ASCO/EHA 2026 — Multiple Myeloma & AL AmyloidosisGuest: Dr. Prashant Kapoor, MD Professor of Medicine, Mayo Clinic, Rochester, MN Chair, Myeloma, Amyloidosis and Dysproteinemia Group, Mayo ClinicEpisode OverviewIn this episode, the hosts sit down with Dr. Prashant Kapoor to review the highest-impact multiple myeloma and AL amyloidosis data from the 2026 ASCO and EHA annual meetings. The discussion centers on the rapidly shifting relapsed/refractory myeloma landscape, where a wave of phase 3 trials of T-cell engaging immunotherapies (bispecific antibodies and CAR T) have now each demonstrated superiority over traditional triplet regimens. Topics Covered1. MajesTEC-3Phase 3, open-label trial of teclistamab + daratumumab SC (n=291) vs. investigator's choice of DPd or DVd (n=296) in 587 patients with relapsed/refractory myeloma and 1–3 prior lines; prior BCMA-directed therapy and anti-CD38-refractory disease were exclusions (only 5% CD38-exposed, none were refractory). Initially presented at ASH 2025, with cytogenetic subgroup data updated at EHA 2026.Key results (34.5-month median follow-up):Median PFS not reached with Tec-Dara vs. 18.1 months with DPd/DVd; 36-month PFS 83.4% vs. 29.7% (HR 0.17)36-month OS 83.3% vs. 65.0% (HR 0.46)Severe infection rate front-loaded: ~35% → ~17% between the first and second 6-month windows, plateauing at ~10–11%/window beyond 12 months; overall grade 3–4 infection 54%, 4.6% fatal infections (mostly without IVIG prophylaxis)EHA 2026 cytogenetic subgroup: 2-year PFS 90% (0 HRCA), 82% (1 HRCA), 76% (≥2 HRCA) — vs. only 14% with DPd/DVd in patients with ≥2 HRCADiscussion points: Applicability to patients at 1st/2nd relapse seen in clinic today; whether infection risk limits use of Tec-Dara at first relapse; implications of the high-risk cytogenetic subgroup data.2. MajesTEC-9Phase 3 trial of teclistamab monotherapy vs. investigator's choice of PVd or Kd in relapsed/refractory myeloma enrolling a heavily anti-CD38-refractory population (100% CD38-exposed, 85% refractory) — the population MajesTEC-3 excluded. Natural comparator: CARTITUDE-4 (phase 3, cilta-cel vs. DPd/PVd in Len-refractory myeloma, 1–3 prior lines, ~25% CD38-refractory/exposed).Key results (~18-month median follow-up):18-month PFS 70% vs. 27% (HR 0.29); 18-month OS 79% vs. 69% (HR 0.6), despite ~2/3 of control-arm patients receiving BsAb/CAR T as subsequent therapyDiscussion points: Cross-trial comparison with CARTITUDE-4 — comparable 18-month PFS on cross-trial comparison, but differing populations (CARTITUDE-4 required Len-refractory disease; MajesTEC-9 enrolled a more CD38-refractory population) and differing maturity (~3-year vs. ~1.5-year follow-up); how Dr. Kapoor chooses between teclistamab and cilta-cel at earlier-line relapse in Len- and CD38-refractory patients, given the divergent toxicity profiles — ongoing infection risk with continuous BsAb dosing vs. the one-time cilta-cel infusion with its rare but potentially irreversible delayed neurotoxicity, IEC-enterocolitis, and CTTLN risk.3. MonumenTAL-3Phase 3 trial — the first phase 3 study of a GPRC5D-targeted bispecific — randomizing 864 patients with relapsed/refractory myeloma (mostly Len-refractory, ~10% CD38-exposed but none refractory) 1:1:1 to Tal-Dara-Pom (n=287), Tal-Dara (n=287), or DPd (n=290), each Talq arm compared against the common DPd control. Presented by Peter Voorhees at EHA 2026 and simultaneously published in NEJM.Key results (24.6-month median follow-up):Both Talq arms significantly improved PFS over DPd: Tal-DP HR 0.28, Tal-D HR 0.33 (both P

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., president and CEO of Mayo Clinic Laboratories, to discuss advancement in Alzheimer's testing and practical uses of artificial intelligence (AI) in healthcare. Later, Dr. Pritt welcomes Chris Garcia, M.D., Mayo Clinic Laboratories' chief digital innovation officer, to explore the evolving role of data in research and development. Innovative Alzheimer's test gets FDA clearance (00:33): Dr. Morice shares how a strategic collaboration is enabling Mayo Clinic Laboratories to offer a newly FDA-cleared blood test for Alzheimer's disease for adults with cognitive symptoms as young as 40.AI helping diagnose rare diseases (03:37): Dr. Pritt and Dr. Morice reflect on a recent article highlighting how AI is helping clinicians identify rare diseases.Data use in research and development (08:16): Dr. Garcia discusses how data, AI, and cross-disciplinary collaboration are advancing research and innovation in laboratory medicine. Note: Information in this post was accurate at the time of its posting.ResourcesC2N Diagnostics: FDA clears C2N Diagnostics' PrecivityAD2® —First Alzheimer's blood test for adults with cognitive symptoms as young as 40Wall Street Journal: AI is helping patients solve medical mysteriesAnswers From the Lab: Digital Advances: What's Next for Clinical Diagnostics?Answers From the Lab: Accelerating Research and Development With BioPharma Diagnostics

Taking the risk no one else will: how Medical 21 is working to replace harvested blood vessels with an artificial coronary artery that becomes part of the patient's own body. In this episode, Manny Villafana, Founder and CEO of Medical 21, returns to discuss his team's progress in developing an artificial coronary artery for bypass surgery. Drawing on more than five decades of medical device innovation, he reflects on how his earlier companies helped create longer-lasting pacemakers and lifelong heart valves that transformed cardiovascular care. Manny explains how Medical 21's graft is designed to grow into a living blood vessel made from the patient's own cells, potentially eliminating the need to harvest vessels during bypass surgery and reducing pain, recovery time, infection risk, and costs. He also shares updates on the company's preclinical progress, partnership with the Mayo Clinic, fundraising efforts, and why pursuing seemingly impossible ideas is essential to advancing medicine. Tune in to learn how bold thinking, regenerative technology, and a willingness to take risks could reshape coronary bypass surgery! Resources: Connect with and follow Manny Villafana on LinkedIn. Follow Medical 21 on LinkedIn and explore their website!

This episode was brought to you by Mouser, our go-to source for electronics parts for any hobby or prototype. Click HERE to discover how additive manufacturing is revolutionizing cornea transplants. Become a founding reader of our newsletter: http://read.thenextbyte.com/ As always, you can find these and other interesting & impactful engineering articles on Wevolver.com.

Epidemiology of Myocarditis   Guest: Leslie Cooper, M.D. Host: Sharonne Hayes, M.D.   Approximately 1,000,000 cases of myocarditis are diagnosed annually with an incidence of approximately 16/100,000.  The incidence is highest in men between 15 and 45 years of age.  However, after age 60 years, women have higher mortality than men. The overall mortality rate is 0.4/100,000.  The rates of diagnosis are double in high SDI regions compared to low STI regions, most likely due to the availability of the pivot all diagnostic tests, cardiac MRI and heart biopsy.  The incidence rates are stable while the death rates have decreased from 1990 to 2023.  Finally, the causes of myocarditis or changing with more cases of immune checkpoint inhibitor related myocarditis which can affect between 0.2 and 1.1% of patients receiving these cancer therapies.   Topics Discussed: How does the epidemiology of myocarditis help inform clinical practice for individual patient management? Are there clinically important sex differences in myocarditis incidence and mortality which practicing physician should be aware of? Are the causes of myocarditis changing? If so, how does a change in etiology affect management?   For more information, review the study below: Klingel, K., Tschöpe, C., Yon, D.K. et al. Global epidemiology of myocarditis: disparities in age, sex and geography. Nat Rev Cardiol (2026). https://doi.org/10.1038/s41569-026-01276-w   Connect with Mayo Clinic's Cardiovascular Continuing Medical Education online at https://cveducation.mayo.edu or on X: @MayoClinicCV  LinkedIn: Mayo Clinic | LinkedIn    Cardiovascular Education App: The Mayo Clinic Cardiovascular CME App is an innovative educational platform that features cardiology-focused continuing medical education wherever and whenever you need it. Use this app to access other free content and browse upcoming courses. Download it for free in Apple or Google stores today! No CME credit offered for this episode.   Podcast episode transcript found here.   Recorded on: 01-April-2026

6 year old Miriam Koska was experiencing leg pain, abdominal pain, fevers, night sweats and fatigue in the fall of 2025 when she was diagnosed with an offshoot of Neuroblastoma known as Ganglioneuroblastoma. This form of Pediatric Cancer has a similar treatment protocol to the more well known Neuroblastoma. Miriam has been through difficult treatment but is doing as well as possible as she enters her next phase of treatment at the Mayo Clinic in Rochester, Minnesota.  

On this Make A Difference Minute, I have Steffenie Jenkins sharing the journey she and her family have faced as they searched for answers for their son, Jacob. Now 21 years old, Jacob is battling bronchiolitis obliterans, a rare and irreversible lung disease, and is receiving treatment through Mayo Clinic in Arizona. As Jacob's health declined, Steffenie found herself in a position many families know all too well. She could see something was wrong, yet finding answers proved difficult. Through countless appointments, tests, setbacks, and frustrations, she continued advocating for her son and pushing forward when it would have been easy to give up. Her message is one of perseverance, determination, and trusting your instincts when someone you love is suffering. Sometimes the path to answers is longer than it should be, but Steffenie's story is a reminder of the power of persistence and a mother's unwavering love for her child. If you would like to support the Jenkins family, visit GoFundMe and search “Starting Over for Mayo.” You can also email Steffenie at SteffenieJenkins@gmail.com for other ways to support. This MADM is brought to you by Bama Estate Planning by Attorney Harlan D. Mitchell, proudly supporting stories and the people who make our communities strong. Real stories. Real people. Real impact. News That Unites!™️

Dr. Dawn Mussallem survived stage 4 cancer, received a heart transplant, and became the first person in history to complete a full marathon just one year later. Her remarkable story doesn't end there. After experiencing unimaginable loss, Dawn found new love in the produce aisle—thanks to a purple sweet potato. And after 25 years at Mayo Clinic, she is beginning another major chapter as chief medical officer at Fountain Life. Dawn joins Chuck Carroll to share her extraordinary journey and the health lessons she has learned along the way. They discuss: The difference between longevity and health span The foods associated with healthier aging Why fiber may be one of the most overlooked health tools Protein needs for active adults and people taking GLP-1 medications The surprising reason Dawn developed prediabetes How sleep can affect blood sugar Personalized nutrition and the gut microbiome Her historic marathon after receiving a heart transplant Finding new love in the produce aisle Her major career move after 25 years at Mayo Clinic Chuck and Dawn will both appear at the Plant Powered Party, September 4–6 in Las Vegas. Explore the complete speaker lineup, schedule, tickets, and current virtual-access information at the link below.

Your annual physical came back "normal," so why do you still feel foggy, tired, and stuck? Dr. Adrijana Kekic says your biology has probably been drifting for years before any standard test notices. Former Mayo Clinic pharmacogenomics specialist and Futurome founder Dr. Adrijana Kekic reveals what a standard 30 to 100 marker panel misses, how multi-omics testing catches metabolic drift early, and why women age differently after 40. After a preventable pulmonary embolism nearly killed her, she rebuilt her own health and now maps cellular aging for people who look fine on paper. Meet our guest Dr. Adrijana Kekic is a pharmacist and nutritionist trained in genetics, one of the first pharmacogenomics clinical specialists at Mayo Clinic and winner of its 2023 Innovation Award. She founded Futurome, a precision health intelligence company that reads thousands of biomarkers to map cellular aging, with a special focus on female biology. Thank you to our partners Outliyr Biohacker's Peak Performance Shop: get exclusive discounts on cutting-edge health, wellness, & performance gear Ultimate Health Optimization Deals: a database of of all the current best biohacking deals on technology, supplements, systems and more Latest Summits, Conferences, Masterclasses, and Health Optimization Events: join me at the top events around the world FREE Outliyr Nootropics Mini-Course: gain mental clarity, energy, motivation, and focus Key takeaways Standard panels lean on late markers; fasting insulin and HOMA-IR flag metabolic trouble years earlier. Multi-omics testing reads thousands of markers across genomics, proteomics, metabolomics, and microbiome. Cellular aging spikes around 40 and 60, the windows where personalization pays off most. The highest mitochondrial density in women sits in the ovaries; decline can surface there before any blood test. Perimenopause is estrogen swinging up and down, not just falling; it hides on standard labs. Women make about 50% less gut serotonin than men, so fasting protocols should differ by sex. Foundation first: sleep, magnesium, vitamin D, movement, and a CGM before advanced interventions. Episode highlights 0:00 Normal labs, hidden aging 6:09 What standard bloodwork misses 18:24 The two aging cliffs at 40 & 60 25:33 The perimenopause you don't notice 30:27 The ICU wake-up call 40:40 Foundation before shiny objects 46:18 Why men & women differ Links Watch it on YouTube: https://youtu.be/1P-vuKmzvtw  Full episode show notes: https://outliyr.com/275 Connect with Nick on social media Instagram Twitter (X) YouTube LinkedIn Easy ways to support Subscribe Leave an Apple Podcast review Suggest a guest Do you have questions, thoughts, or feedback for us? Let me know in the show notes above and one of us will get back to you! Be an Outliyr, Nick

The medical community is trying many approaches to help push back against the advance of Alzheimer's and dementia. One leading institution is taking a different and unconventional approach to supplement the traditional treatments. Special Correspondent Megan Thompson reports for our coverage of the intersection of health and arts, part of our CANVAS series. PBS News is supported by - https://www.pbs.org/newshour/about/funders. Hosted on Acast. See acast.com/privacy

How much of your marketing technology budget is quietly underperforming, not because the software is flawed, but because your teams can't, or won't, fully adopt it?Because real agility was never about buying faster tools. It's about having an operating model that can actually turn a tool's potential into results, and keep doing it as the tools keep changing.Today we're digging into the phase that quietly decides whether any martech investment pays off: what happens after the contract is signed with things like implementation and adoption. We'll get into:- Why rollouts stall — and why the real cause is usually the operating model, not the tool.- What it takes to move a team from "trained" to genuinely changed.- How to measure real value without fooling yourself with usage metrics.- And what shifts once the platform starts doing some of the work itself.To help me discuss this topic, I'd like to welcome, Kate Dalbey, Chief Client Officer at Qualified Digital.About Kate DalbeyAs CCO, Kate leads client management and growth initiatives at Qualified Digital, bringing over 20 years of digital marketing experience from both client-side and agency-side roles. She's responsible for driving organic and net new growth by leading multi-disciplinary teams who turn light-bulb ideas into fantastic outcomes for the brands QD works with. Kate is guided by the client philosophy that "we grow because they grow." Kate has consistently delivered year-over-year growth in her portfolio within fast-paced, high-growth start-up environments. She passionately believes that digital experiences can change people's lives for the better and works diligently to see these outcomes arrive in real time. In her daily life at QD, Kate enjoys what she calls "the relentless pursuit of better business results" and takes pride in building the teams that can create them, from idea to strategy to plan to execution and measurement. Because what's next isn't enough, it's what's north that really gets her excited. Kate's career experience is deeply rooted in healthcare, across provider, payer, and life sciences. The client roster she's managed includes category powerhouses CVS Health, CommonSpirit Health, Mayo Clinic, Kaiser Permanente, Cigna, Aetna, Sunrise Senior Living, Gelesis, UNCH, Jefferson Health, Cedars-Sinai, Spaulding Rehabilitation, UHS, and Wedgewood Pharmacy. She's also led digital transformation for AmeriGas, Hitachi Vantara, Thomson Reuters, ScanSource, U of Pennsylvania, and the Am. Board of Internal Medicine. When Kate isn't delivering her unique brand of magic at QD, she's with her husband and 2 sons. She loves cheering on Philly sports teams, coaching youth soccer with her husband, and traveling with her family.Kate Dalbey on LinkedIn---------- Resources ---------- Qualified DigitalThe Agile Brand podcast is brought to you by TEKsystems.We're proud to be a media partner for #MAICON26 - Oct. 13-15! Learn how AI can power your marketing and business and help you grow smarter. Use code AGILE150 to save!Reach your customers with Reddit. Spend $500 in ad spend, get $500 back in ad credit!Chaser is the only Slack-native project management platform that helps teams turn messages into tracked tasks, automate follow-ups, and maintain team-wide visibility, without adopting another tool. Now integrated with Claude and other GenAI tools. Use code AGILEBRAND for a 3-month free trial (normal trial is 14 days).The most influential minds in software, AI, and engineering leadership will be at WeAreDevelopers World Congress North America, September 23-25 in San Jose. Start building your own apps with Replit and get $20 off.Enjoyed the show? Tell us more at and give us a rating so others can find the show.Connect with Greg on LinkedInDon't miss a thing: get the latest episodes, sign up for our newsletter and more.Check out The Agile Brand Guide website with articles, insights, and Martechipedia, the wiki for marketing technology.The Agile Brand is produced by Missing Link. Hosted on Acast. See acast.com/privacy for more information.

Host: Darryl S. Chukta, M.D.  Guest: Robert D. McBane, M.D.  At times, pulmonary embolism can be very challenging to diagnose. While some patients have a very dramatic presentation, others may have very subtle, non-specific symptoms. Establishing a diagnosis quickly is important as a delayed or missed diagnosis can lead to excessive morbidity and mortality. What clues might a patient have that should alert us to the possibility of a PE? What are the best tests to order when we suspect one? Do all patients with a PE need to be hospitalized, and what are the current recommendations for management? My guest is vascular medicine specialist, Dr. Robert McBane, M.D., from the Department of Cardiovascular Medicine at the Mayo Clinic. We'll cover these questions and more as we discuss “Pulmonary Embolism”.  Connect with us! Mayo Clinic Talks Podcast Season 6 | Mayo Clinic School of Continuous Professional Development 

In this episode, you'll hear: The latest science on preventing Alzheimer's, and why dementia may be more preventable than you think The critical overlap between heart health and brain health, and how “multi-disease risk reduction” works The real role of the APOE gene, what genetic testing can (and can't) tell you, and actionable steps if you carry risk markers A nuanced look at new Alzheimer's blood tests: who should get them, and what to consider before you do Dr. Dani Cabral, an Ivy League-trained neurologist and psychiatrist, joins Dr. Robert Todd Hurst to share proactive strategies for maintaining sharp cognition for life. Discover why hope is warranted, how lifestyle changes can dramatically alter your risk, and the importance of social connection on both brain and heart health. Connect with Dr. Dani Cabral here : 

Chronic Total Occlusion   Guest: Abhiram Prasad, M.D. Host: Paul Friedman, M.D.   Chronic total occlusions are frequently encountered and are associated with complex coronary artery disease and diffuse atherosclerosis. Percutaneous coronary intervention is a suitable option for relieving angina in select patients who remain symptomatic despite optimal medical therapy. Success rates of over 80% can be routinely achieved by CTO operators with MACE rates of less than 5%.   Topics Discussed: Who is the ideal patient for CTO PCI? Which practices in CTO PCI maximize success and minimize risk? Is there a role of viability testing when evaluating patients for CTO PCI? Is there a role for non-culprit CTO PCI for complete revascularization post AMI? Is there any new clinical trial data for CTO PCI? Are there any new devices for CTO PCI?   Connect with Mayo Clinic's Cardiovascular Continuing Medical Education online at https://cveducation.mayo.edu or on X: @MayoClinicCV  LinkedIn: Mayo Clinic | LinkedIn    Cardiovascular Education App: The Mayo Clinic Cardiovascular CME App is an innovative educational platform that features cardiology-focused continuing medical education wherever and whenever you need it. Use this app to access other free content and browse upcoming courses. Download it for free in Apple or Google stores today! No CME credit offered for this episode.   Podcast episode transcript found here.   Recorded on: 14-April-2026

Paul Lunter didn't start out trying to build a wellness empire — he was in construction, watched someone in pain step in and out of the shower for relief, and built a machine instead. Thirty-seven years later, that machine (HydroMassage) has grown into WellnessSpace Brands: five product lines, 400 million sessions delivered, and installations in 50+ countries at Planet Fitness, Life Time, Gold's Gym, and beyond. Lunter walks Eric Malzone through the company's medical-market origins, the R&D behind machines like the PolarWave Dry Plunge and the company's newest RedZone sauna which uses no wood, and why he thinks recovery is a permanent industry shift rather than another fitness fad. Key Takeaways

This week we're focusing on how healthcare is using AI systems. The NHS is firmly set on a course of AI integration, with NHS England committing £10 billion of taxpayer funds to the cause over the next three years. The pressure to implement AI in our hospitals is intense. But, how can healthcare leaders know what makes for a good AI adoption strategy? Victor Montori and Jon Tilburt are physicians from the US' Mayo Clinic. They join us to lay out what they are calling the ‘five red flags' that any organisation needs to consider in its AI rollout.   The UK is already having this conversation. The National Commission into the Regulation of AI in Healthcare released its initial report in June of this year. Among its findings was a call for a ‘lifecycle-based approach' to regulation. To explain what this means, as well as how doctors can be equipped to ‘surveil' AI systems as conditions evolve, we're joined by the co-authors of a new BMJ editorial - Mark Ball from the University of Derby, and Elvira Perez Vallejos from the University of Nottingham.   And lastly, we talk about a research paper from last week that sparked off some concern. Researchers at Stanford University in California have used generative AI to design novel bacteriophage viruses. But, what have these scientists actually accomplished, and how can we put the right safeguards around the technology? Simon Clarke, associate professor in cellular microbiology at the University of Reading, explains the breakthrough and lays out its real implications.   References: We can, but should we? Red flags for hasty, low integrity AI integration into healthcare Regulating AI in healthcare: a moving target Developments in AI designed viruses demonstrate why such research must be done in the open

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., president and CEO of Mayo Clinic Laboratories, to discuss “rabbit fever” cases in New York and strategies for responding to industry trends. Later, Dr. Pritt welcomes Mary Jo Williamson, Mayo Clinic Laboratories' chief administrative officer, to share practical strategies for leading teams through periods of rapid change.Strategies for making strategic progress amid disruption (00:29): Discover practical insights from a recent Forbes article by Dr. Morice on identifying healthcare industry disruptors and determining how organizations should respond.A rare tick-borne illness (07:21): Learn about suspected cases of the rare tick-borne illness tularemia, also known as "rabbit fever.”Leading through change (09:02): Williamson shares lessons from more than three decades of healthcare leadership, offering practical guidance for helping teams navigate change with confidence and purpose.ResourcesForbes: Understanding healthcare industry disruptors and what comes nextTick-borne disease: An expanding threatFive steps to manage change in an outreach laboratoryMary Jo Williamson talks resiliency and agility on Fierce Healthcare podcastMary Jo Williamson shares strategic investment insights with Modern Healthcare

Henry talks with the owner of Carroll's Corn in Rochester Seamus Kolb about taking over the company from the original owners, what Carroll's Popcorn means to Rochester, partnering with Scheel's, proximity to the Mayo Clinic, future plans and more!

Newsflash: Long, unbroken stretches of sitting appear to carry health risk beyond the daily total of sitting. But breaking them up can help even when the total hours spent sitting number doesn't budge. A listener asked about NEAT -- the energy burned by the movement of ordinary life that isn't exercise -- and the answer turned out to have little to do with calories and a lot to do with staying strong and mobile as we age! LET'S TALK THE WALK! Join here for support, motivation and fun! Wellness While Walking Facebook page Walking to Wellness Together Facebook GROUP Wellness While Walking on Instagram Wellness While Walking on Threads Wellness While Walking on Twitter Wellness While Walking website for show notes and other information wellnesswhilewalking@gmail.com     RESOURCES AND SOURCES (some links may be affiliate links) Exercised: Why Something We Never Evolved to Do Is Healthy and Rewarding by Dr. Daniel Lieberman (Pantheon, 2021) — the source of the energy-conservation reframe and the point about hunter-gatherers sitting roughly as much as we do. Fed Up: What Evolution Reveals About Food, Diet, Health, and Eating Well by Dr. Daniel Lieberman (Knopf, August 2026) — his new book, which we'll be discussing in a future episode. Move Your DNA: Restore Your Health Through Natural Movement by Katy Bowman (Propriometrics Press, 2nd edition 2017) — the source of the idea that movement works like a diet, with walking as one nutrient rather than the whole menu. Mentioned in this episode: Dr. James Levine — the Mayo Clinic researcher who coined the term NEAT in the 1990s while studying weight gain. His best-known study overfed volunteers roughly 1,000 extra calories a day for eight weeks; fat gain varied widely across the group, and those who gained least tended to be the ones whose everyday movement increased to meet the surplus. Levine JA, Eberhardt NL, Jensen MD. "Role of Nonexercise Activity Thermogenesis in Resistance to Fat Gain in Humans." Science, 1999. The Stanford fitness tracker study — seven wrist-worn devices tested against lab-grade equipment in 60 volunteers. Six of the seven measured heart rate within 5% error. None measured energy expenditure well: the most accurate device was off by an average of 27%, and the least accurate by 93%. Stanford Medicine news summary — Shcherbina et al., Journal of Personalized Medicine, 2017. Sitting time in older adults — reviews of objectively measured sedentary behavior put adults 65 and older at roughly 8.5 to 9.5 hours of sitting a day, more than any other age group, with long uninterrupted bouts associated with cardiovascular disease, blood sugar trouble, frailty, and in some studies higher dementia risk. Breaking up sitting and physical function — a pilot study in frail older adults found improvements in Timed Up and Go and sit-to-stand scores when participants broke up their sitting, even without reducing total sedentary time. Harvey et al., "Stomp Out (Prolonged) Sitting" pilot — note this is a small pilot; treat the finding as promising rather than settled. Movement as a diet — the idea that walking is one nutrient rather than the whole menu reflects Katy Bowman's work, particularly Move Your DNA and Movement Matters. Two small moves from this episode ●    Break up the sitting. Once an hour or so, stand and move, even briefly — refill the water, walk to the mailbox, unload a few dishes. Right after a meal is a particularly good moment, since movement after eating has been shown to soften the blood sugar rise. ●    Attach movement to moments that already exist. The kettle boiling, a phone call, a commercial break, a trip to the printer, the end of a chapter. Decide once what the movement will be, and let variety in — balance on one foot at the counter, reach for a high shelf, get down to the floor and back up. A reminder Carolyn is not a doctor or mental health professional. Content presented here is for educational and informational purposes only. Please check with your doctor before making any health or lifestyle changes.     HOW TO RATE AND REVIEW WELLNESS WHILE WALKING How to Leave a Review on Apple Podcasts on Your iOS Device 1.   Open Apple Podcast App (purple app icon that says Podcasts). 2.   Go to the icons at the bottom of the screen and choose "search" 3.   Search for "Wellness While Walking" 4.   Click on the SHOW, not the episode. 5.   Scroll all the way down to "Ratings and Reviews" section 6.   Click on "Write a Review" (if you don't see that option, click on "See All" first) 7.   Then you will be able to rate the show on a five-star scale (5 is highest rating) and write a review! 8.   Thank you! I so appreciate this!   How to Leave a Review on Apple Podcasts on a Computer  1.   Visit Wellness While Walking page on Apple Podcasts in your web browser (search for Apple Podcasts or click here)  https://www.apple.com/apple-podcasts/ 2.   Click on "Listen on Apple Podcasts" or "Open the App" 3.   This will open Apple Podcasts and put in search bar at top left "Wellness While Walking" 4.   This should bring you to the show, not a particular episode – click on the show's artwork 5.   Scroll down until you see "Rating and Reviews" 6.   Click on "See All" all the way to the right, near the Ratings and Review Section and its bar chart 7.   To leave a written review, please click on "Write a Review" 8.   You'll be able to leave a review, along with a title for it, plus you'll be able to rate the show on the 5-star scale (with 5 being the highest rating) 9.   Thank you so very much!! OTHER APPS WHERE RATINGS OR REVIEWS ARE POSSIBLE Spotify Goodpods Overcast (if you star certain episodes, or every one, that will help others find the show)  Castbox Podcast Addict Podchaser Podbean   HOW TO SHARE WELLNESS WHILE WALKING Tell a friend or family member about Wellness While Walking, maybe while you're walking together or lamenting not feeling 100% Follow up with a quick text with more info, as noted below! (My favorite is pod.link/walking because it works with all the apps!) Screenshot a favorite episode playing on your phone and share to social media or to a friend via text or email! Wellness While Walking on Apple – click the up arrow to share with a friend via text or email, or share to social media Wellness While Walking on Spotify -- click the up arrow to share with a friend via text or email, or share to social media Use this universal link for any podcast app: pod.link/walking – give it to friends or share on social media Tell your pal about the Wellness While Walking website Thanks for listening and now for sharing! : )       DISCLAIMER Neither I nor many of my podcast guests are doctors or healthcare professionals of any kind, and nothing on this podcast or associated content should be considered medical advice. The information provided by Wellness While Walking Podcast and associated material, by Whole Life Workshop and by Bermuda Road Wellness LLC is for informational and entertainment purposes only. It is not intended to be a substitute for professional medical advice, diagnosis or treatment. Always seek the advice of your physician or other qualified health care provider with any questions you may have regarding a medical condition or treatment, and before undertaking a new health care regimen, including walking.     Thanks for listening to Wellness While Walking, a walking podcast and a "best podcast for walking"!

What if a decades-old infection-control rule isn't actually making eye care safer and is instead damaging equipment, generating unnecessary plastic waste, and costing the health care system millions?  In this episode, we are joined by Mayo Clinic glaucoma specialist, Dr. Cheryl Khanna, to discuss a potentially practice-changing position statement from the American Glaucoma Society and American Academy of Ophthalmology on tonometer disinfection. The group explores why longstanding high-level disinfection requirements may deserve reconsideration, including the lack of confirmed infections transmitted through tonometry, potential damage to Goldmann tonometer tips from high-level disinfection, and the unique antimicrobial properties of the ocular surface.  Tune in to hear evidence supporting physical cleaning and low-level disinfection for appropriately selected patients.  Finally, the conversation tackles the financial and environmental consequences of disposable devices in ophthalmology and what still needs to happen before these recommendations translate into widespread changes in clinical practice.   Subscribe to the podcast:  https://MayoClinicOphthalmology.podbean.com  Follow and reach out to us on X and IG: @mayocliniceye

Host: Darryl S. Chutka, M.D.  Guest: Ruti Sella Svetlit, M.D. Cataracts are one of the leading causes of vision impairment, especially among older adults. While cataract surgery has been available for many decades, it has evolved significantly over the last several years. Patients now have multiple lens options which can give them a variety of benefits. How has cataract surgery changed over time? What are some of the new, current lens options available? What can patients expect from them and are all individuals with cataracts candidates for these new options? In today's podcast, we'll explore how cataract surgery has changed, and which patients may benefit the most from this newer technology as we discuss “Innovations and New Options for Cataract Surgery” with my guest, Dr. Ruti Sella Svetlit, M.D., an ophthalmology surgeon from the Mayo Clinic.  Connect with us! Mayo Clinic Talks Podcast Season 6 | Mayo Clinic School of Continuous Professional Development 

What if vascular disease could be detected years earlier, before patients face the most serious consequences?In this episode of Entrepreneur Rx, host John Shufeldt sits down with Josh Hanson, founder and CEO of ImageAiD, a Jetstream Venture Fund portfolio company, to discuss his path from biomedical engineering student to healthcare entrepreneur. Josh shares how growing up in Rochester, Minnesota, surrounded by Mayo Clinic and a culture of healthcare innovation, shaped his desire to build technology that could help save lives. The conversation explores the problem ImageAiD is working to solve: diagnosing peripheral artery disease, or PAD, earlier and at scale. Josh explains how ImageAiD combines handheld Doppler ultrasound, cloud-based software, and AI to help clinicians capture and analyze blood flow waveforms in minutes, reduce diagnostic variability, and identify vascular disease risk earlier. John and Josh also discuss Mayo Clinic mentors, ASU's Biodesign training, building for all healthcare stakeholders, and turning peer-reviewed research into a platform that can reach patients. Beyond the technology, the episode covers entrepreneurship at a young age, imposter syndrome, humility, mentorship, and the courage to simply start. About Josh Hanson: Josh Hanson is a biomedical engineer, entrepreneur, and founder focused on advancing cardiovascular diagnostics through medical technology and AI. As founder and CEO of ImageAiD, he is leading the development of an AI ultrasound platform designed to improve early detection of peripheral artery disease and broader cardiovascular risk. His work has been shaped by experience at Mayo Clinic's Gonda Vascular Center, ASU's biomedical engineering program, and the Mayo Clinic and ASU Alliance for Health Care's IMPACT Program, where he trained in the Biodesign process. About ImageAiD: ImageAiD is a medical technology company developing a handheld Doppler ultrasound platform that combines portable hardware, cloud-based software, and AI to make vascular disease easier to detect before it causes life-altering complications. The platform is designed to capture and analyze blood flow waveforms in minutes, helping clinicians identify signs of peripheral artery disease and better understand a patient's risk of serious cardiovascular events, including heart attacks, strokes, and amputations. Initially focused on PAD, ImageAiD aims to make vascular diagnostics faster, more consistent, and more accessible in settings where traditional vascular testing may not be available. About Xcellerant Ventures: Xcellerant Ventures is a venture capital firm that invests in innovative companies across healthcare, technology, defense, and other emerging industries. Through multiple funds and investment vehicles, including the Jetstream Venture Fund, Xcellerant partners with visionary founders, provides strategic guidance, and helps connect investors with opportunities in the private markets. About Jetstream Venture Fund: Jetstream Venture Fund is an interval fund managed by Xcellerant Ventures, that seeks to provide investors access to early-stage, high-growth companies with flexible terms, lower minimums ($5,000 minimum), and no carried interest. Jetstream is one of the first funds of its kind, bringing venture-style investing opportunities to a wider professional audience. Disclosure for Jetstream: Investors should carefully consider the investment objectives, risks, charges, and expenses of the Fund before investing. The prospectus contains this and other information about the Fund and can be obtained by emailing jetstream@sweaterfunds.com or by visiting www.jvf.vc. Please read the prospectus carefully before investing. 

Tricuspid Repair and Replacement in the Cath Lab: A New Era   Guest: Mackram Eleid, M.D. Host: Malcolm Bell, M.D.   In this episode of “Interviews With the Experts,” Mayo Clinic consultant in interventional cardiology Dr. Mackram Eleid explored the evolving landscape of transcatheter therapies for tricuspid valve disease. Listeners will hear an overview of current indications, benefits, and risks associated with transcatheter tricuspid repair and replacement. The discussion highlighted key factors that influence the choice between repair and replacement, reviewed current evidence, and examined important knowledge gaps and emerging data that may shape future clinical practice.   Topics Discussed: What is the current threshold to recommend tricuspid intervention in a patient TR? What are the strengths and weaknesses of transcatheter tricuspid repair versus replacement? What evidence in the field is still needed?   Connect with Mayo Clinic's Cardiovascular Continuing Medical Education online at https://cveducation.mayo.edu or on X: @MayoClinicCV  LinkedIn: Mayo Clinic | LinkedIn     Cardiovascular Education App: The Mayo Clinic Cardiovascular CME App is an innovative educational platform that features cardiology-focused continuing medical education wherever and whenever you need it. Use this app to access other free content and browse upcoming courses. Download it for free in Apple or Google stores today! No CME credit offered for this episode.   Podcast episode transcript found here.   Recorded on: 18-January-2026

Full show notes: https://bengreenfieldlife.com/dylan In this episode with Dylan Gemelli, you'll hear one of the wildest origin stories in the health world. Dylan went from college athlete to Milan model to cocaine dealer to a 15-year prison sentence, and came out on the Fourth of July with two felonies, no job prospects, and a decision to start over. Within a year he had a million YouTube subscribers explaining compounds almost nobody was talking about yet, and today he hosts the number one health and fitness podcast in the country. You'll also get the practical side: what SARMs really are and why he turned against steroids, what happened when a routine calcium score came back at 120 with an Lp(a) of 330, how he pushed back against the Mayo Clinic and got that number down into the 90s anyway, and what he learned about ejection fraction and chronic cardio the hard way. Dylan explains why he believes many biohackers are among the unhealthiest people out there, how stacking too many supplements and peptides creates redundancy that backfires, and which lesser-known peptides will rise in popularity. Episode Sponsors: LMNT: Everyone needs electrolytes, especially those on low-carb diets, who fast, are physically active, or sweat a lot. Go to DrinkLMNT.com/BenGreenfield to get a free sample pack with your purchase. Dr. Murray Natural Products – ThymoQuin®: A clinically researched black seed oil that supports healthy cortisol levels, resilience to everyday stress, and overall well-being, and the only one that meets U.S. Pharmacopeia guidelines. Visit doctormurray.com/ben and use code BEN25 for 25% off all Dr. Murray Natural Products. Manukora: You haven't tasted honey like this before, so try some honey with superpowers from Manukora. Head to manukora.com/ben or use code BEN to get $25 off your Starter Kit. Quantum Upgrade: Research shows the Quantum Upgrade increased ATP production in human cells by 20 to 25%. Unlock a 15-day free trial with code BEN15 at quantumupgrade.io. Active Skin Repair: Uses hypochlorous acid, a molecule your body naturally produces, to support skin repair and defense without harsh chemicals. Go to ActiveSkinRepair.com and use code BEN for 20% off, or find it on Amazon and at your local CVS.See omnystudio.com/listener for privacy information.

Ben Lindbergh and Meg Rowley banter about MLB franchise appreciation, Stat Blast about what the resurgence of three-inning saves and the expanding distribution of saves say about pitcher usage, and learn about a new baseball injury. Then (43:28) they bring on Lindsay Imber of Close Call Sports and the official scorer behind the MLB Scoring Changes account to explain the “fourth-out” rule that confused fans and players this week and to pick nits with the MLB rulebook. Finally (1:30:50), Ben brings back former major leaguer John Poff to read from his new book, reflect on his use of “greenies” and players’ political differences, and share a new fundraising initiative for the Standing Rock Reservation, followed (2:13:45) by a few updates. Audio intro: The Spaghettis, “Effectively Wild Theme” Audio interstitial: The Shirey Brothers, “Effectively Wild Theme” Audio outro: Ted O., “Effectively Wild Theme” Link to Yankees “capital infusion” Link to story about Yankees valuation Link to story about Lakers sale Link to impending Padres sale Link to FIFA takeover attempt Link to Infantino wiki Link to Littleton save Link to save rule Link to pope hat giveaway Link to Latz stats Link to Atlanta’s three-out savers Link to data on three-out saves Link to data on save-getters by season Link to multi-inning RP outings data Link to Herfindahl–Hirschman index wiki Link to annual HHI data Link to HHI graph Link to Inverse Participation Ratio Link to THT on three-inning saves Link to SB Nation on three-inning saves Link to Medium post on three-inning saves Link to WSJ closers story Link to Ben on saves slipping in 2017 Link to Betteridge’s law wiki Link to parakeet bounceback news Link to Goodhart’s law wiki Link to league SP splits Link to league RP splits Link to FG post on Goodhart’s law Link to other FG post on Goodhart’s law Link to Arrigheti report Link to more on Arrigheti Link to Morton’s neuroma wiki Link to Morton’s neuroma causes Link to Mayo Clinic on Morton’s neuroma Link to more on Morton’s neuroma Link to even more on Morton’s neuroma Link to Ben on the 2015 ALDS game Link to Ben on confused counts Link to @ScoringChanges Link to @ScoringChanges fourth-out tweet Link to @CloseCallSports Link to Close Call Sports website Link to Close Call Sports YouTube channel Link to Lindsay wiki Link to Lindsay’s fourth-out video Link to Lindsay’s Sale video Link to Lindsay’s Wheeler video Link to fourth out wiki Link to fourth-out story 1 Link to fourth-out story 2 Link to SABR on fourth outs Link to The Athletic fourth-out explainer Link to Bois on balks Link to Sam on balks Link to xkcd comic Link to Schneider quote Link to 2016 Schneider game Link to Strike Four Link to Poff Stat Blast Link to first Poff appearance Link to second Poff appearance Link to Halls of Fame discussion Link to Poff’s first Hall of Fame Link to Poff’s second Hall of Fame Link to Poff’s book Link to Carlin routine Link to baseball exceptionalism wiki Link to greenies info Link to Ben on PEDs and the ball Link to “Buffalo Bill ‘s” poem Link to Standing Rock wiki Link to Gilbert Kills Pretty Enemy art Link to John’s fundraiser Link to Scherzer’s piano-playing Link to Kendrick cameo story Link to Skenes velo graph Link to Skenes game story Link to Liquid I.V. powder Link to Rocker pickle-juice game Link to Stanton yoga report Link to Foulke wife tweet Link to Foulke firing report Sponsor Us on Patreon Give a Gift Subscription Email Us: podcast@fangraphs.com Effectively Wild Subreddit Effectively Wild Wiki Apple Podcasts Feed Spotify Feed YouTube Playlist Facebook Group Bluesky Account Twitter Account Get Our Merch! var SERVER_DATA = Object.assign(SERVER_DATA || {}); Source

August 13, 2026: Your daily rundown of health and wellness news, in under 5 minutes. Today's top stories: Viome acquires Circulate Health, launching Viome Pro and adding treatment capability to its diagnostics and nutrition platform across 200+ clinics Clair Health partners with Mayo Clinic Platform_Accelerate to clinically validate its continuous hormone and symptom monitoring wearable, launching in November Oura signs tennis stars Coco Gauff and Taylor Fritz as brand ambassadors ahead of the US Open, adding to partnerships with soccer stars Harry Kane and Declan Rice Today's episode is brought to you by AIIR — a modern communications and experiential agency for health, wellness, fitness, and performance brands. From earned media to events and creator-led campaigns, AIIR helps companies sharpen their story, earn attention, and build trust that compounds. Visit https://aiir.agency to learn more. More from Fitt: Fitt Insider breaks down the convergence of fitness, wellness, and healthcare — and what it means for business, culture, and capital. Subscribe to our newsletter → insider.fitt.co/subscribe  Work with our recruiting firm → https://talent.fitt.co/ Follow us on Instagram → https://www.instagram.com/fittinsider/ Follow us on LinkedIn → linkedin.com/company/fittinsider  Reach out → insider@fitt.co 

Listen to today's podcast... What is your burden to blessing ratio? How often do you catch yourself complaining about something and how often are you outwardly expressing gratitude? For most of us, we spend far too much time looking at the negative and the difficult and not nearly enough looking at the positive and the awesome. Take One Action Today To Build Your #Resiliency!  Here are today's Tips For Building Resiliency and Celebrating Admit You're Happy Month: The more that we focus on the positive and the awesome, the bigger the impact it will have on our happiness. Admitting that we are happy, increases our happiness. And it encourages others to admit to being appreciative and happy in their lives. So celebrate the brief moments that make you smile, and the occasions that knock your socks off! Dr. Amit Sood, Professor of Medicine and the Mayo Clinic, states that life's happiest moments have one or more of these three ingredients: Creating, Connecting, Caring. What positive things have happened to you today? Acknowledge all of them. Be proud of who you are. Celebrate yourself. Keep a positive mental attitude. You'll feel better, live better, and be happier. If you like today's wellness tips, let me know. You can leave me a review on amazon or through your #alexa app. Discover how to take small steps towards a healthier, happier, less-stressed you by visiting my website at worksmartlivesmart.com #mentalhealth #hr

OPENER: Stephen A Smith DESTROYS WNBA After HIDING BRITTNEY GRINER'S DIRTY SECRET! Defend Sophie Cunningham! - 5:11 Brandon Gill Gets Witness To Admit Who DEI Punishes - 5:13 “I went to court to argue what a woman is” — Sall Grover at ARC 2026 -1:00 Jason Arday Whistleblower: ‘People Knew The Truth And Covered It Up' - 4:00 Quick, easy, worthless: Students let AI do the thinking | Principia Scientific, Intl. - Text It's Time to Save America - 10:00   HEALTH NEWS Arginine Supplement May Strengthen Immune Response to Cancer and Viral Infections Yeast food supplement helps immune cells fight cancer more effectively Physical activity linked to lower stroke and death risk in adults with atrial fibrillation Phthalates may contribute to high blood pressure in pregnant women Daily Collagen Supplement Alters Bone-Related Blood Markers in Female Runners, Study Says Arginine Supplement May Strengthen Immune Response to Cancer and Viral Infections Rockefeller University, August 10, 2026 (Natural News) A study published in the journal Cell reports that arginine, an amino acid found in protein-rich foods and produced by the body, may help the immune system recognize and respond to cancer and viral infections. The research found that low arginine levels were linked to reduced production of MHC-1, a protein that displays abnormal cellular signals to T cells, according to the report. In mouse models, arginine-rich diets were associated with fewer colon tumors and milder influenza and SARS-CoV-2 infections, the researchers reported. The findings add to prior work linking declining immune function to cancer progression. When arginine is scarce, cells struggle to produce MHC-1 proteins, which appear on the surfaces of cells throughout the body and display foreign or abnormal proteins to T cells. Researchers repeated the dietary studies using mouse models of influenza and SARS-CoV-2, conditions previously associated with unusual levels of different amino acids. One of the most dramatic patterns to emerge was that arginine was the most depleted amino acid in all of these diseases. Not only did mice with an arginine-rich diet have milder symptoms from viral infections, giving the mice arginine after influenza infection improved their outcomes too. Yeast food supplement helps immune cells fight cancer more effectively Trinity College Dublin & University College Dublin, July 9 2026 Researchers from Trinity College Dublin (TCD) and University College Dublin (UCD) have shown for the first time that a food supplement made from yeast helps the body to make stronger immune cells that can fight cancer. The research teams found that adding a yeast-based supplement to the food of obese laboratory mice changes how their immune cells grow and help to make better cancer‑fighting cells. Mice were fed a standard or high fat diet supplemented with yeast beta-glucan for 4-12 weeks and then their immune system was challenged by different types of cancer cells (colorectal, skin and breast cancer). The study also tested whether yeast supplementation could overcome immune dysfunction caused by obesity and whether protective effects persist after weight loss. Crucially, this dietary intervention restores anti-tumor innate immunity in obese mice and reverses long-term immune memory defects that persist even after weight loss, a major unmet clinical challenge. Physical activity linked to lower stroke and death risk in adults with atrial fibrillation Arctic University of Norway, August 5 2026 (News-Medical) Being physically active was linked to a lower risk of stroke and death for adults with atrial fibrillation, or AFib, according to new, independent research published in the Journal of the American Heart Association. AFib is a quivering or irregular heartbeat that occurs in the heart's upper chamber known as the atria. According to the American Heart Association, it can lead to blood clots, stroke and other heart-related conditions. The prevalence of AFib in the U.S. was estimated at 4.48% of the adult U.S. population. The study tracked more than 87,000 adults in Norway for about 15 years, capturing information about AFib, stroke and death from national health registries. What did the analysis find? Compared to adults who were inactive, adults with a low, moderate or high level of physical activity had a 9%, 19% and 18% lower risk of stroke, respectively. Having a low, moderate or high level of physical activity was associated with an 11%, 18% and 22% lower risk of death from any cause, respectively. For people with AFib, staying active was tied to living an average of 0.5 to 1.2 years longer compared to those who were inactive Phthalates may contribute to high blood pressure in pregnant women Harvard School of Public Health, August 10 2026 (News-Medical) Phthalates, which are chemicals found in plastics, personal care products and hundreds of other consumer goods, may contribute to high blood pressure in pregnant women, according to a study published in the Journal of the Endocrine Society. The researchers measured phthalate exposure and blood pressure in 338 pregnant women at three points during pregnancy. They analyzed whether higher levels of these chemicals-individually and in combination-were linked to higher blood pressure or an increased risk of pregnancy-related high blood pressure disorders. The authors found that pregnant women with higher urine concentrations of fragrance-associated phthalates and those in personal care products had higher systolic and diastolic blood pressure markers of an increased risk of hypertensive disorders of pregnancy. About 13% of participants in the study developed a pregnancy-related high blood pressure disorder. Women with higher levels of certain phthalates, especially those found in personal care products, tended to have higher blood pressure later in pregnancy. Daily Collagen Supplement Alters Bone-Related Blood Markers in Female Runners, Study Says Fitchburg State University, University of Connecticut & Mayo Clinic, August 4 2026 (Natural News) A four-week randomized, double-blind, placebo-controlled trial found that female distance runners who took 20 grams of collagen peptides per day showed an approximately 5.1 percent rise in P1NP over four weeks, a blood marker of bone formation, while the placebo group showed no such change, according to a study published in Frontiers in Nutrition. The collagen group also showed a drop in IL-6, an inflammatory protein linked to bone breakdown, while placebo levels held steady or rose, the study reported. The trial included 22 female runners ages 18 to 35 who ran at least 35 miles per week, and no adverse effects were reported. Collagen is the most common and abundant protein in the body, accounting for about 30 percent of total protein content and providing structural support to bones, tendons, ligaments, and other connective tissues, according to published research.       Discussion about this episode

Nutrition, supplements, and what the evidence saysIn this episode, I'm joined by Chelsey Hoffmann, PA-C, RDN, who specializes in pain medicine at Mayo Clinic, to break down where nutrition fits into chronic pain management and how to evaluate supplements without overpromising results.We cover:Why a Mediterranean-style diet should come before supplements for painSupplements with evidence for neuropathic pain vs. musculoskeletal painWhat we know about alpha-lipoic acid, turmeric/curcumin, glucosamine, chondroitin, collagen, omega-3s, magnesium, vitamin D, and PEAChelsey's algorithm for experimenting with supplements How to define whether a supplement is actually “working”Medication interactions and patient populations that require extra cautionWhen nutrient deficiencies should be investigated before adding another supplementResources mentioned:Episode 75: Are Your Patients Taking Too Many Supplements and Don't Even Know It?Episode 73: Is That Supplement Worth It? Connect with Chelsey Hoffmann on LinkedInAny Questions? Send Me a MessageSupport the showConnect with Colleen:InstagramLinkedInSign up for my FREE Newsletter - Nutrition hot-topics delivered to your inbox each week.Disclaimer: This podcast is a collection of ideas, strategies, and opinions of the author(s). Its goal is to provide useful information on each of the topics shared within. It is not intended to provide medical, health, or professional consultation or to diagnosis-specific weight or feeding challenges. The author(s) advises the reader to always consult with appropriate health, medical, and professional consultants for support for individual children and family situations. The author(s) do not take responsibility for the personal or other risks, loss, or liability incurred as a direct or indirect consequence of the application or use of information provided. All opinions stated in this podcast are my own and do not reflect the opinions of my employer. 

Jacquelyn Fletcher Johnson is an executive communication strategist, keynote speaker, conference designer, and founder of the Heartwood Leadership Institute. She helps leaders, founders, and organizations transform powerful ideas into unforgettable messages that inspire action through the power of story. The belief that stories can change lives has shaped her work from the very beginning.   Jacque has coached executives and advised leaders at Fortune 100 companies and global brands including Amazon, Accenture, General Mills, Salesforce, Stripe, Target, Visa, Walmart, and more. She's the host of the Ideas Love Community podcast, creator of the Gateway Gathering & Pitch Fest, and the author of 14 books. She's trained thousands of professionals in communication, executive presence, and thought leadership. When she's not launching voices, you'll likely find her paddling with her gold medal-winning dragon boat team of all breast cancer survivors.   Episode Summary:   In this episode of Heartbeat for Hire, host Lyndsay Dowd sits down with Jaquelyn Fletcher Johnson — communication strategist, conference designer, 14-time author, and founder of the Heartwood Leadership Institute. Jaquelyn traces her lifelong obsession with storytelling back to a childhood prank on her younger brothers, then walks through a career that wound from freelance writing and magazine editing into pioneering "Creative Writing at the Bedside" and an on-set interview show at Mayo Clinic, and eventually into executive coaching and leadership development.   Key Takeaways:   - Stories shape how people feel long after they're told. - "Trail angels" are the people who show up right when you need them. - A meandering career can still add up to a clear pattern. - Starting something of your own means giving up full control. - Executive presence isn't about polish — it's about being grounded. - A health scare can clarify your legacy. - You don't have to act on every calling — but it won't disappear.   Episode Chapters:   00:00 Cold open: three things you'll learn from this episode 00:43 Welcome to Heartbeat for Hire + guest introduction 01:36 Jaquelyn joins the show 02:08 Origin story: the Jolly Green Giant and the power of story 04:58 Career path: freelance writer to magazine editor to Mayo Clinic storytelling programs 08:33 What is a "trail angel"? 10:06 The tough reality of the conference and speaking world 10:43 Why Jaquelyn decided to build her own conference 14:25 Lessons learned building the Gateway Gathering and Pitch Fest 17:53 Listener thank-you and sponsor spotlight (Cozy Earth) 18:34 Redefining executive presence 21:19 What inspires Jaquelyn 22:01 Legacy, breast cancer, and dragon boat racing 23:18 What's next: Gateway Gathering, Pitch Fest, and family milestones 24:04 Where to find Jaquelyn 24:09 Final takeaway for listeners

GLPs are everywhere right now — but do you actually know what they are or what they do? In this episode I break down the reality of GLP-1, what it is, how it works, and how your body already has the natural ability to activate it through a fasting-focused lifestyle. Whether you're considering the shot or just curious about how it all works, this episode gives you the full picture so you can make the best decision for your health and future. _____ Are you ready for real, compassionate support on your fasting journey from someone who has actually lived it? I've shed over 200 pounds through fasting and have maintained it through some of the hardest seasons of life. If you're tired of doing this alone, you don't have to anymore. Come find your people: The Fasting Support Club _____ REFERENCES Habener, J.F. (2004). The discovery of glucagon-like peptide 1. ScienceDirect — Molecular and Cellular Endocrinology. Retrieved from sciencedirect.com Mass General Brigham Newsroom. (2025). Joel Habener receives Breakthrough Prize in Life Sciences for contributions to GLP-1 medications. Retrieved from massgeneralbrigham.org Journal of Clinical Investigation. (2024). Joel Habener, Svetlana Mojsov, and Lotte Bjerre Knudsen awarded Lasker Prize for pioneering work on GLP-1. Retrieved from jci.org Eng, J. (1992). Discovery of exendin-4 in Gila monster venom. VA Medical Center, Bronx, NY. Referenced in: PlexusDx. (2026). History of GLP-1 drugs: Complete timeline from exenatide to tirzepatide. Retrieved from plexusdx.com Fella Health. (2025). What is GLP-1 lizard venom: Gila monster discovery to diabetes drugs. Retrieved from fellahealth.com U.S. Food and Drug Administration. (2005). Approval of exenatide (Byetta) for type 2 diabetes. FDA Drug Approval Database. Acosta, A. & Ghusn, W. (2023). Semaglutide shown to be effective for weight loss in multicentre, one-year real-world study. European Congress on Obesity (ECO2023). Presented by Precision Medicine for Obesity Program, Mayo Clinic. Retrieved from eurekalert.org Mayo Clinic Press. (2026). Health benefits of semaglutide beyond weight loss. Retrieved from mcpress.mayoclinic.org National Institutes of Health / NCBI. (2024). Patient perceptions of Ozempic (semaglutide) for weight loss: Mixed methods analysis of online medication reviews. Retrieved from ncbi.nlm.nih.gov National Institutes of Health / NCBI. (2024). Evaluation of pre-treatment assessment of semaglutide users: Balancing the benefits of weight loss vs. potential health consequences. Retrieved from ncbi.nlm.nih.gov Fung, J. (2016). The Obesity Code: Unlocking the secrets of weight loss. Greystone Books. Fung, J. (2025). The Hunger Code: Resetting your body's fat thermostat in the age of ultra-processed food. Greystone Books.

How could Mayo Clinic's Global AI Platform transform personalized care? In this episode of Mayo Clinic's Tomorrow's Cure, host Lindsey Seavert reports from PlatforMed in Scottsdale, Arizona, where leaders in medicine, technology, AI, and policy explore how connected healthcare platforms can bring together data, expertise, and innovation to improve patient care around the world. Seavert speaks with Dr. Micky Tripathi about safely scaling AI at Mayo Clinic, including over 450 clinical AI solutions. Dr. Gelareh Zadeh discusses how AI, digital pathology, and automation could democratize access to advanced diagnostics, making specialized expertise and high-quality care available to patients around the world. Dr. John Halamka and COO Maneesh Goyal describe Mayo Clinic Platform's three-sided model connecting data, innovators and care organizations globally through reciprocal data networks, while collaborators from Google Cloud and Aga Khan University discuss de-identified multimodal data, equity for low and middle-income countries, and AI applications from digital pathology to community health impact. How to listen and stay connected: Subscribe to Tomorrow's Cure on your favorite podcast app and follow the show so you never miss an episode. Get the latest health information from Mayo Clinic's experts—subscribe to Mayo Clinic's newsletter for free today: https://mayocl.in/3EcNPNc Connect with Mayo Clinic: Like Mayo Clinic on Facebook: https://www.facebook.com/mayoclinic/ Follow Mayo Clinic on Instagram: https://www.instagram.com/mayoclinic/ Follow Mayo Clinic on X (formerly Twitter): https://x.com/MayoClinic Follow Mayo Clinic on Threads: https://www.threads.net/@mayoclinic

Host: Darryl S. Chutka, M.D.  Guest: Stephanie L. Grach, M.D., M.S.  Chronic fatigue syndrome is now known as myalgic encephalomyelitis. Despite this change in terminology, there's still a great deal that's not known regarding this health problem. Clinical manifestations can include severe, persistent fatigue, often with a worsening of symptoms following physical exertion. Impaired sleep, potential cognitive impairment, and possible orthostatic intolerance is also commonly seen. The exact cause remains unknown, although several proposed mechanisms have come forward. The diagnosis is based on clinical presentation. Patient management, while less than optimal, is usually limited to symptom control. This condition poses a major challenge to primary care clinicians with both establishing a diagnosis and management. To help sort out this frustrating health problem is my guest, Dr. Stephanie Grach, an internist in the Division of General Internal Medicine at the Mayo Clinic. The topic for today's podcast is Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.  Connect with us! Mayo Clinic Talks Podcast Season 6 | Mayo Clinic School of Continuous Professional Development 

Aortic Stenosis in the Younger Patient in 2026   Guest: Mackram Eleid, M.D. Host: Malcolm Bell, M.D.   Dr. Malcolm Bell interviews Dr. Malcolm Eleid on the diagnosis and management of aortic stenosis in younger patients, as well as discussing patient-centered decision-making considerations for lifetime management of aortic stenosis. After review, listeners will understand current indications as well as advantages and disadvantages of transcatheter versus aortic valve replacement for younger patients with aortic stenosis.    Topics Discussed: What factors are taken into account when considering lifetime management of aortic stenosis? Can valve in valve be performed inside of a transcatheter aortic valve replacement (TAVR) prosthesis? Who are the patients that are better served with surgical aortic valve replacement (SAVR)?   Connect with Mayo Clinic's Cardiovascular Continuing Medical Education online at https://cveducation.mayo.edu or on Twitter @MayoClinicCV and @MayoCVservices. LinkedIn: Mayo Clinic Cardiovascular Services Cardiovascular Education App: The Mayo Clinic Cardiovascular CME App is an innovative educational platform that features cardiology-focused continuing medical education wherever and whenever you need it. Use this app to access other free content and browse upcoming courses. Download it for free in Apple or Google stores today! No CME credit offered for this episode.   Podcast episode transcript found here.   Recorded on: 28-January-2026  

In this insightful episode of Parallax, Dr Ankur Kalra is joined by Dr Barry Borlaug, Professor of Cardiology at Mayo Clinic and one of the world's leading experts in cardiac haemodynamics, for a comprehensive discussion on the evolving landscape of heart failure with preserved ejection fraction (HFpEF). Together, they explore the complexities of diagnosing and managing a syndrome that continues to challenge clinicians. Dr Borlaug explains why exercise right-heart catheterisation remains the gold standard for uncovering "hidden" HFpEF, particularly in patients with normal resting filling pressures, and provides a detailed overview of the Mayo Clinic's invasive exercise testing protocol. The conversation also traces the evolution of HFpEF phenotyping, from the traditional hypertensive patient to the increasingly recognised obesity-driven phenotype, highlighting the role of systemic inflammation, visceral adiposity and disease progression across the HFpEF spectrum. Dr Borlaug outlines what he describes as the modern therapeutic backbone for HFpEF in 2026, reviewing the evidence supporting SGLT2 inhibitors, mineralocorticoid receptor antagonists including finerenone, and incretin-based therapies such as semaglutide and tirzepatide. Looking ahead, he discusses emerging investigational approaches including sotatercept, the challenges facing device-based therapies, and the importance of identifying HFpEF mimics such as cardiac amyloidosis and hypertrophic cardiomyopathy to ensure patients receive the most appropriate treatment. Questions and comments can be sent to "podcast@radcliffe-group.com" and may be answered by Ankur in the next episode. Host: @AnkurKalraMD and produced by: @RadcliffeCardio Parallax is Ranked in the Top 100 Health Science Podcasts (#48) by Million Podcasts.

We're joined by Nik Suresh, director of Hermit Tech and excellent blogger on the software industry. You might know Nik for an incredible essay he wrote a couple years ago about piledriving anybody who mentions AI. Well he's back at it with another great piece analysing the AI mania that has seemingly possessed every manager in every institution in every sector. We chat about where this mania comes from, how it's manifesting, and what happens when reality eventually catches up to these delusions. ••• Nik's company website: https://hermit-tech.com/ ••• AI Mania Is Eviscerating Global Decision-Making https://ludic.mataroa.blog/blog/ai-mania-is-eviscerating-global-decision-making/ ••• I Will Fucking Piledrive You If You Mention AI Again https://ludic.mataroa.blog/blog/i-will-fucking-piledrive-you-if-you-mention-ai-again/ ••• Lawsuit Claims the Mayo Clinic's Use of AI Is Butchering Patient Care https://futurism.com/health-medicine/lawsuit-mayo-clinic-ai-tools-hospital-maya Standing Plugs: ••• Order Jathan's book: https://www.ucpress.edu/book/9780520398078/the-mechanic-and-the-luddite ••• Subscribe to Ed's substack: https://substack.com/@thetechbubble ••• Subscribe to TMK on patreon for premium episodes: https://www.patreon.com/thismachinekills Hosted by Jathan Sadowski (bsky.app/profile/jathansadowski.com) and Edward Ongweso Jr. (www.x.com/bigblackjacobin). Production / Music by Jereme Brown (bsky.app/profile/jebr.bsky.social)

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., president and CEO of Mayo Clinic Laboratories, to discuss Protecting Access to Medicare Act (PAMA) reform and recent reports about the New World screwworm. Dr. Morice also shares insights on building an innovation strategy that delivers meaningful organizational value.PAMA reform update (00:40): Dr. Morice discusses the status of the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act and PAMA.Tracking the New World screwworm (02:24): Learn about recent cases of the New World screwworm, why this parasitic fly is problematic, and how sterile insects help contain it.Developing an innovation strategy that drives value (04:49): Discover lessons from Dr. Morice's experience developing a strategic approach to innovation that delivers meaningful outcomes and impact.Resources4 steps to establishing a new approach to innovation

In this episode, Lyell K. Jones Jr, MD, FAAN, speaks with Karin G. Johnson, MD, FAAN, who served as the guest editor of the August 2026 Sleep Neurology issue. They provide a preview of the issue, which publishes on August 3, 2026. Dr. Jones is the editor-in-chief of Continuum: Lifelong Learning in Neurology® and is a professor of neurology at Mayo Clinic in Rochester, Minnesota. Dr. Johnson is a Professor in the Department of Neurology at the University of Massachusetts Chan School of Medicine–Baystate and the Sleep Medicine Division Chief at Baystate Medical Center in Springfield, Massachusetts Additional Resources Read the issue: continuum.aan.com Subscribe to Continuum®: shop.lww.com/Continuum Continuum® Aloud (verbatim audio-book style recordings of articles available only to Continuum® subscribers): continpub.com/Aloud More about the American Academy of Neurology: aan.com Social Media facebook.com/continuumcme @ContinuumAAN Host: @LyellJ Guest: @drsleepykarin  Full episode transcript available here Dr Jones: This is Dr. Lyell Jones, Editor-in-Chief of Continuum. Thank you for listening to Continuum Audio. Be sure to visit the links in the episode notes for information about subscribing to the journal, listening to verbatim recordings of the articles, and exclusive access to interviews not featured on the podcast.  Dr Albin: All right, welcome all. For the first time ever in the history of Continuum Audio, we are coming to you live from Chicago here at the AAN annual meeting. And now over to your host, the one and only editor-in-chief, Dr. Lyell Jones.  Dr Jones: Welcome, everybody. My name is Lyell Jones, editor-in-chief of Continuum, and I'm here today with Dr. Karin Johnson, and we're interviewing Dr. Johnson for the upcoming and recently published issue of Continuum on Sleep Neurology. We have been doing Continuum Audio for a while, but we're doing something different this time. As our listeners online can tell, we are recording this for the first time ever with a live studio audience at the American Academy of Neurology annual meeting in Chicago, Illinois. So, this is a fun experience for us. I hope it's been fun so far for you, Dr. Johnson.  Dr Johnson: Great to be here.  Dr Jones: It's great to have you. So, before we get into the interview, I do wanna introduce our team here for the live recording of the podcast. You've already heard Dr. Casey Albin's voice. Dr. Casey Albin is an associate professor of neurology at Emory University. Also serves as one of our associate editors at the journal and one of our Continuum Audio interviewers. So, she's going to be working the crowd today. Let's have a round of applause for Dr. Albin. And our guest of honor today is Dr. Karin Johnson. Dr. Johnson is a professor of neurology at UMass Chan Medical School and, Baystate Medical Center in Massachusetts. She is a world-renowned expert in sleep neurology and is the guest editor for the most recent issue of Continuum on Sleep Neurology. Dr. Johnson, welcome. Why don't you introduce yourself to our audience?  Dr Johnson: You did a great introduction, but I'm a clinical sleep medicine specialist. Spend my days seeing patients, taking care of people with narcolepsy, sleep apnea, restless legs, everything that comes my way. And then I have a side interest in doing sleep medicine advocacy, especially for permanent standard time.  Dr Jones: And we may get to that. I mean, that might be part of our conversation today. So, you've now read all of the articles in this issue, and it's a really great issue. There's a lot of new developments in sleep neurology. There are some updates for clinicians, people who see patients with sleep disorders that I think are, are timely and important updates. You have this unique view because you have just read all of these articles, really good articles by expert authors. When you read through these, Dr. Johnson, what was the biggest, what was the biggest thing that surprised you?  Dr Johnson: I think the biggest surprise for me is just so many changes in, in all of these articles. I realized how easy it was for us to make a journal that is so different from a few years ago. Whether it's Dr. Stahl's obstructive sleep apnea and new ways to think about endotyping sleep apnea that is gonna have treatment implications or the new treatments that are out there like tirzepatide, the changes that we're having with restless leg treatment. I particularly wanted to have a chapter on circadian neurology that Dr. Abbott did a great job really highlighting how if we think about the timing of when we give meds, the timing of when we eat, how that really can help neurological health, brain health, overall health, as well as mental health and cognition, especially as the AAN thinks about brain health as a whole, not just treating our patients, but how we can treat the population of people by improving sleep. I like how we hit on all these different areas in this issue.  Dr Jones: And I don't know how you managed to do it. They're just a small number of articles. We cover a lot of existing territory with well-characterized diseases, with new advances. But there's a lot of new stuff in sleep, and so somehow, it's all packed in there. It's really impressive. One of the things I was gonna ask you about was an evolution, and this has been a number of years now in how we manage restless leg syndrome. When I was training, it was all about dopamine agonists, and that was your first line. And over time, the evidence has supported moving away from that, and now we have more recent guidelines that have come out, and it's really the alpha-two delta-one calcium channel antagonists. How is that transition going? Do you still see people in practice who come in on dopamine agonists? How is that going? How's the field responding to that?  Dr Johnson: That's one of my most frequent restless leg consults. So even though it's been years since I have really initiated dopamine agonists in my patient, every day we get in people often on very high doses of dopamine agonists, and their doctors have just been escalating and escalating these meds over the years, and they come in with horrible augmentation. Their symptoms are much worse than they used to be, happening earlier in the day. And so, trying to get these patients off of these meds that are addictive, the way I like to teach about it is these dopamine agonists are the Fioricets of the sleep world. We know they work great, but in the long run, the patients are gonna be worse overall. And so, it's so hard to get people off these dopamine agonists, just like it's so hard to convince a headache patient that they don't need their Fioricet and that they're gonna be better off if we can get them off of it. What I think has really changed is we have more options to use. So, the alpha-delta-like agonists like gabapentin are now considered first line, but there's a lot of patients who they just don't work well enough with or they don't tolerate. And so, what do you do in that case? It's easy when that works, but and, when that doesn't work, we are being much more aggressive these days with iron replacement, potentially even trying to push ferritin levels in refractory patients up to three hundred, and using IV iron rather than just oral iron to get over the absorption issues to get the brain levels high enough. Motor stimulators, little cuffs that kind of go around the leg and stimulate the peroneal nerve in a certain way that not only can give people immediate relief, but also some data that suggests that over time it actually lessens their restless legs. We have agents like dipyridamole that work on the adenosine system in a sort of new novel pathway at addressing restless legs. And then the opiates, often meds like methadone or Suboxone can be used in some patients. But as we're getting more of these other options, often we don't need to go to those levels because we do have more to work with.  Dr Jones: So, the key point is lots of options. We're not starting with dopamine agonists anymore. And I think the fact that you're still seeing a lot of patients who have been initiated on that probably tells us there's an education gap field that we need to work on. So, another thing that I noticed reading through the issue was, and this feels like a change over the last few years, is the availability and the tendency to use in-home sleep apnea testing as opposed to formal, traditional in-lab. And that feels like a great new option, and maybe that increases and improves availability for patients who need access to the test. But how do you work through that?  Dr Johnson: So, I love in-home testing. We've been using it for over a decade. Other parts of the country where insurances didn't sort of mandate it are now being more mandated. I think the real change happened for a lot of places over the pandemic when labs closed down. But I think it's good because it brings a lot more patients to us. They get tested, they get tested quicker. People who would say, "I would never go into a lab. Oh, I'll do a home study." So, it just does bring more people in, and it gets them to treatment that they need that can really be life-changing. But it's not for everybody. The biggest people are people that have other bad pulmonary issues. If you're on oxygen therapy, you should not be getting a home study. That really should be a group of people that come in the lab. Similarly, if you have bad COPD, you probably should be getting a full in-lab study, so we can get more monitoring. Central sleep apnea is an interesting one. It can be very hard in some cases to differentiate the centrals and obstructive nature as well on a home study. Doesn't mean you can't do a home. So, if it's a person that just can't get an in-lab study easily, maybe you start with the home. If it looks purely obstructive, and you're all set, then you got an answer, and you can move on. But if you get back a home study that looks questionably central, they're gonna need to come into that lab. So, if you already know they're high risk because they're on narcotics, cause they have congestive heart failure, it's usually worth going straight to the lab. But again, you may consider a home study based on the patient. Patients that really cannot use the equipment can also be an issue. So, if they've had a debilitating stroke and have no one to help them put on that device, or cognitively they just can't handle the device, they're gonna be someone who's gonna benefit from coming into the lab and getting the help from the techs. So, those are the big populations that you might go starting for a home. And then the other thing that confuses a lot of people, the home is only for diagnostics. It really isn't for treatment. So, I have patients that say, "Oh, like, you can just titrate my CPAP with a home study." No. So if it's a treatment decision where they're not doing well on treatment, or I need to figure out do they need CPAP or BiPAP or IVAPS or one of these more complicated treatments, those are people that are gonna need to come into the lab to get that treatment portion of the evaluation.  Dr Jones: What a great summary. That's like everything I needed to know about who do I need to bring into the lab and who do I think maybe could do an at-home study. Really great. And speaking of devices, I think all of us who see patients in the room here and our listeners out there online have experienced patients, and this feels like a very recent phenomenon to me, are coming in with their commercial at-home wearable device. And they have printouts sometimes, and they show me their phone, and they give me some numbers that I don't really know how to interpret. Reading through this issue, I learned a couple of great new words. I learned about orthosomnia, right? So, people who become so preoccupied with their sleep, it keeps them awake at night, literally, right? I mean, it's a complete paradox. I learned about nearables, so things that aren't necessarily wearables that are just in the room while the patient is sleeping that monitor proxies for sleep quality, sleep stage, and other things. And I frankly, I'm not really sure what to tell patients. So, what do you tell patients who come in with all the data? Like, or how do you tell patients to use these?  Dr Johnson: I think these devices can go both ways. So, I do kind of say the pros and cons of these devices. I think for a lot of patients, they're empowering. It's getting them to think about sleep, to wanna know how good their sleep is. Are they getting enough sleep? So, if it's used in those ways, it's gonna be very helpful. I actually had a patient last week, and they noted that they're having big desats all night and could show me essentially an overnight oximetry data rather than me having to order it, and I had days of data, which sometimes can be too much. But in this case, it's like, oh, when he was on his side that night, he looked a lot better, so I can use that to give advice to the patient about particular treatments. He actually went down to Mexico, and a doctor friend gave him oxygen therapy while he was there randomly. And we could see on the nights that he had the oxygen therapy, it did really help his central sleep apnea pattern. And so that pushed us towards saying, "Let's qualify you for that up here in the States." So, I think in some cases it can give really important data. Now, I saw a posting on social media the other day of someone saying, "Can I get advice on how to improve my REM sleep? My tracker says I have no REM sleep, and I need to do something about it." There's really not data to support needing to do something about it. And so, I do think it can get some people on these wild goose chases, trying to get to a certain percentage of sleep. And these trackers, they're good in a lot of ways, but they're not perfect. He could be getting REM sleep that the tracker on him does not show. You want to relate it to what symptoms are they having. I think they can be very good for trying something out. So, let's say someone, has their tracker telling them they get five hours of sleep, and they try this intervention, and that helps them show that they got the seven hours of sleep, or they went from no REM to REM and it goes in the right direction. It can help give them that positive feedback that something they're trying, is working. But the absolutes for any given patient, it's hard to over-- What does it mean if it says you've got a 50% score versus a 70% score? That may or may not be meaningful in any given person, but again, they can compare themselves to themselves. If they were a lower score and now they're a higher sleep score because they did something that was meaningful, and that goes along with them feeling better, that can help give them that positive feedback to do something good.  Dr Jones: So, a little bit of a mixed picture.  Dr Johnson: Yeah.  Dr Jones: Sometimes they help. Sometimes they distract. Hopefully- Dr Johnson: And as a provider, sometimes it can be overwhelming because they're like, "Come look at my year's worth of data." And you're like, "No."  Dr Jones: Yeah.  Dr Johnson: You know, let me see one page or two pages of data and be like, "Yep, okay, I get it." Dr Jones: Just show of hands in the audience, who in the room wears a sleep device at night, like a ring or a, some kind of sleep monitoring app? That's about half the audience.  Dr Johnson: This is why they're here.  Dr Jones: So that's really helpful, and I think it is. You want to be supported by the data. You want to be supported by evidence and high-quality biometric evidence. Another big trend, and this has been a number of years in the making, is the understanding, Dr. Johnson, of the relationship between sleep physiology and neurodegenerative disease. One of the things I love about neurology is there's still so much left to learn about the normal physiologic functioning of the brain. So glymphatics and other aspects of sleep physiology that we didn't know about a decade or two ago. When you think about how that relationship has developed, sleep physiology, maybe sleep disorders and neurodegenerative disease, how has that changed your approach to talking to patients? Do you counsel patients differently now because of what we understand better about that?  Dr Johnson: Yeah, I mean, we are still limited with our data. We have so many studies that show the associations between whether it's not enough sleep, too much sleep, or having a sleep disorder like obstructive sleep apnea, and that being a risk factor for stroke or Alzheimer's or Parkinson's. But we still sort of lack the treatment trials that necessarily say, "If you treat obstructive sleep apnea, you're gonna have less dementia," or, "You're gonna be less likely to have that stroke." So, we have a lot of physiological studies, a lot of reasons why it makes sense, but we don't have that final, nail in the coffin to say, "If you do this, you'll definitely be better." So, we know certain groups are more at risk. If you have obstructive sleep apnea and you are symptomatic, you seem to have higher cardiovascular risk. If you have a person who's had a stroke and we find a milder case of sleep apnea, and they're someone that's totally asymptomatic. They say, "I sleep fine. I feel fine." There's not great data to say, "If you treat your sleep apnea, you're gonna be less likely to have a stroke." Now, if they come in and they're sleepy and their sleep apnea is really severe, and they have more hypoxic burden, which is also more connected with a lot of these risks, I'm going to say, "I think you are in the higher risk group of sleep apnea people who it's probably gonna be more likely to help your cardiovascular risk, your dementia risk." We can counsel them, and then it's really a personal decision. Some people are like, "No way. I'm never gonna use a CPAP machine, ever." And other people are like, "You know, my mom had a stroke. My dad had Alzheimer's. I want to do every possible thing I can to make it less likely that I have this outcome that I want to avoid." And so, you're going to take that in to, you know, do you want to try this treatment or not? It's a lot easier when you have outcomes that you can follow, like, "If I try CPAP, does my blood pressure get better? Do I stop having AFib attacks?" It's a lot harder when, will I or not get Alzheimer's ten years down the road or have that stroke?  Dr Jones: It's hard to get people to do things for kind of an abstract prevention down the road, but could be important. Are there trials going on that are going to assess this data?  Dr Johnson: Yeah. We currently have a big trial getting people right away, right after their stroke, on CPAP, and not only looking at prevention, but also looking at recovery outcome. It's been running for several years. Hopefully, we'll get enough data to close out the study coming up.  Dr Jones: We'll look forward to that.  Dr Johnson: Yeah.  Dr Jones: So, I'm really excited to get to our audience here, but before we do that, I do want to ask Dr. Johnson one more question. Dr. Johnson is famous for her advocacy for sleep in general, but specifically related to Standard Time. So, let's do a little experiment here. I didn't warn Dr. Johnson about this, so we'll see how she does. She does a ton of advocacy. She's a pro. So, pretend like we're in DC, and I'm a senator, and we just got in an elevator. You're going to give me your elevator pitch on what we should do.  Dr Johnson: So, you know, sleep is one of the few essential things in life. We need to eat, we need to drink, we need to have clean air, and we need to sleep and when we improve sleep, we can improve basically every outcome, whether it's academics, whether it's productivity, whether it's our physical health, our mental health. And the problem is we structure our lives in a way that really keep people, and especially our teenagers, from getting the sleep they need. And one of these structural things we do is permanent daylight savings time. Essentially, what you're doing is you're putting the sun out later, makes it harder to go to bed. I was just talking to someone, the sun's going down at 9:00, and you need to get your kid to sleep at 7:30, 8:00 so they can get the amount of sleep they need. That is almost an impossible task because their circadian rhythms are being pushed later, they can't fall asleep on time. Then you're setting their clocks an hour earlier, so when that alarm clock is going off at 6:00 AM in the morning, it's actually 5:00 AM in the morning. You're squeezing sleep from both sides, and it's basically impossible to get enough sleep. A lot of people think the only problem with daylight savings time is twice a year with the changes, and there are certainly harms related to that. So, a lot of people think if we went to permanent daylight savings time it would be better, and we got rid of those changes. What they don't realize is that permanent circadian misalignment by setting the sun more ahead, at 1:00 to 2:00 instead of at noon causes the sleep and circadian disruption all year round that leads to increased incidents of strokes, of heart attacks, of obesity, of cancer, of suicides, of depression, of worse academic grades. Again, pretty much every outcome you have there that relates to brain health, we have now data that shows that it's worse. And so, we can improve our lives if we can go to permanent Standard Time.  Dr Jones: You convinced me. How about that? If there were any skeptics in the room, I doubt there are any left. We only went to like the fifth floor there, and she... I'm like, "I'm voting for this. Whatever, whatever this bill is, I'm gonna vote for it." So, I'm excited to get to the audience here. Before we get to questions and answers, and we want you to get your questions ready for Dr. Johnson. I do have a couple of trivia questions. And we've been doing this for a little while now on the podcast. The first trivia question actually relates to arts and culture.  Dr Jones: What famous artist used transitions between sleep and wake states to inspire his art? Anybody know?  Guest Speaker 1: Is it Van Gogh?  Dr Jones: Not Van Gogh that I know of. There in the back.  Guest Speaker 2: Picasso.  Dr Jones: Picasso, not that I know of. Right here.  Guest Speaker 3: Salvador Dali.  Dr Jones: Salvador Dali. We have a winner. Thank you for your answer. So apparently, I read this. Salvador Dali would sit in a chair holding onto a metal key and wait until he fell asleep, and it would fall out of his hands and drop into a bowl, and it would wake him up. So, then he would pick it back up, and he would go in and out of sleep trying to generate hypnagogic hallucinations, basically, and he would use that to inspire his art. And you think about his art, maybe that kind of makes sense. All right, now I've got a neurology trivia question. Okay, so maybe we're a little more comfortable with the neurology trivia in here. What is the center in the brain that is responsible for REM sleep atonia?  Guest Speaker 4: The receptor is for erection in the lateral hypothalamus.  Dr Jones: That is not correct. REM sleep atonia. Right here.  Guest Speaker 4: Emilio Malgona, Hyannis, Massachusetts. Dorsal raphe nucleus.  Dr Jones: We'll give you credit for that. Very good. Excellent. So, the-  Dr Johnson: Well, no. That's actually the serotonin. He's talking about another one.  Dr Jones: Oh, I thought I heard, I thought I heard-  Dr Johnson: You heard dorsal  Dr Jones: ... I heard dorsolateral tegmental nucleus of the pod.  Dr Johnson: Not quite.  Dr Jones: You get a prize anyway, sir, just for, just for answering. Thank you very much. All right. So, we're all warmed up here. So, Dr. Albin, what do you think? Should we get some questions from the audience?  Dr Johnson: All right, we've got some questions.  Guest Speaker 5: I have a statement and a question.  Dr Jones: Please tell the podcast your name again, sir.  Guest Speaker 5: Steve Spar, New York City. The tyranny of the morning people. You don't want people, you don't want the sun to go down too late because it'll keep people up longer. I spent my whole life fighting people like you. I am a nighttime person. Why do I have to go to sleep earlier? I want to go to sleep later. I want to wake up later. I don't want to wake up at 7:00 in the morning. I want to wake up at 10:00. There's a certain tyranny that we must use circadian rhythms of the majority, and it persecutes people like me who are night people.  Dr Johnson: So that is a great question.  Guest Speaker 5: What say you?  Dr Johnson: What say me is actually the harms of daylight savings time are actually to the night owls, and don't really affect the morning people. I can still go to sleep on time and get up on time without that pressure of needing to go to work. The night owl people, they can't fall asleep until later. They want to sleep in earlier, but we're forcing them to get up an hour earlier for work and school. And because we're doing daylight savings time, you're not getting the morning light you need, you're getting too much light at night, and you are more sensitive to a delay in your circadian rhythm, which makes you even more of a night owl and increase the degree of social jet lag. So, we actually see that the harms and risks of things like depression, cardiovascular risks are much greater in night owls than they are in normal people or morning larks. And this is again why the risks are the highest for our teenagers, who are essentially all night owls. You're making it harder for them to fall asleep on time. You're making them more and more of a night owl that it becomes more out of line with our standard social schedule. So, what we can do for a night owl is say to our schools, say to life that we want to change our society norms of getting up early. But that has nothing to do with daylight savings time. That has to do with how we make our schedule Dr Jones: All right, next question. And introduce yourself to the audience.  Guest Speaker 6: Sure. I'm Sanjay Rathi from New Haven area, Neurology. Movement disorders, Parkinson's disease, sleep disruptions, sleep-regulating REM, RBD issues, what are your recommendations? And as things get worse, what additional intervention should we do?  Dr Johnson: Yeah, I think it's hard with a lot of our neurodegenerative disorders, it's a two-way sleep. The disorders themselves often worsen sleep quality, have decrease in their sort of circadian amplitudes, and so that can affect sleep ability. And so, trying to do the things that promote sleep, like getting lights down in the evening, keeping things dark and quiet, doing cognitive behavioral sort of therapies if that's needed can all be helpful. Very high incidence of obstructive sleep apnea or other sleep-disordered breathing, whether it's Parkinson's or other neurodegenerative disorders, so evaluating and treating that if need be. And some of these people, especially as they get later on, you may end up considering medication for insomnia because their underlying disorders was causing it and there's, and you're not going to CBTI your way out of it. We do have the new orexin antagonist sleep agents, which are more recommended for older people and probably safer agents than your Z drugs and some of the other sleep meds out there. So, some people should be on some of those meds if their sleep is so disrupted. I've seen some sleep studies where it's basically like wake, sleep, wake, sleep, wake, sleep all night long. And it's like, wow, you really cannot sustain sleep, and we think it's not just a behavioral thing. I think it is part of their underlying Parkinson's and underlying disorders that can really cause major sleep disruption.  Dr Jones: It's a great question. Before we get more from the audience here, Dr. Albin, I'm just curious, you know, you got some questions from online. Don't know if any of those stood out to you. And the other thing is, I think about your practice, Dr. Albin, as a neurointensivist, there's some great content in this issue on how to maintain an adequate sleep environment in the hospital and the importance of that for the acute episode, maybe for some long-term outcomes. When I was reading the article, I didn't really didn't think about the ICU setting. That must be-- what do you do in the ICU?  Dr Albin: Well, we happen to have a question about just that. Dr Jones: Well, there you go  Dr Albin: From Dr. Manners of Baltimore, Maryland. "What meds should I be giving patients in the ICU or the inpatient setting to preserve or recalibrate their sleep-wake cycles? Is there anything that we can do besides just getting them out of bed during the day?"  Dr Johnson: Meds are always hard cause as sleep doctors, we're usually the last one to recommend meds. But there are situations and scenarios where meds may be appropriate. I can't say what's one better than the other, and some of the meds we have probably aren't even available as options in the hospital. So, the, you know, again, the orexin antagonist may be a good class to try to use, but they may not be an option. There was a good study that looked at empowering the patient and whether or not the ICU patients are empowerable. But they give a card to the patients in the hospital and say, "Tell your nurse to turn off my TV and my lights. Do I need all the blood draws all throughout the night, or can it be put off to the morning?" And trying to empower the patient to ask for these things and do some of the behavioral things. And they found that doing that did improve the duration of sleep, did reduce some of the number of awakenings that people ended up having at night. So, I think the ICU is a very particular population where there's a lot of things you can't get rid of. But certainly, turning on the lights, turning off the lights, and trying to limit noises as much as you can, in those night hours, trying to give some sense of a 24-hour day. The other thing is feeding is really important to circadian rhythms. I had a patient that had a brain bleed and, after it, she just her circadian rhythms were just off, and part of it was she was getting tube feeds through the night. So, one of the very first interventions we did was to move her timing of her feeding so that it wasn't in sleep, and that really did help make a difference in getting her back on a pattern, along with light therapy and other behavioral techniques as well.  Dr Jones: It's a great question.  Dr Albin: Absolutely. I mean, I think that validates just that we spend a lot of time actually asking like, "Can we feed people during the day?" Or, "Can we, can we limit the amount of baths that are happening at 3:00 in the morning?" We also had another one from the audience that came from Dr. Lavina Singla of Mississippi, and I think a lot of our patients are asking this question. Is melatonin addictive?  Dr Johnson: Is melatonin safe? Is melatonin addictive? I think with any sleeping aid, people become addictive to what they perceive is the outcome. So, if they said, "This got me to sleep, and now I'm sleeping great, I don't want to come off of it." And so, you get this to meds that are truly addictive, but even meds that aren't felt to have that addiction, there is certainly a behavioral change. And that's a lot of what cognitive behavioral therapy is working with these patients on, is challenging that belief of maybe it isn't the med, maybe it's your internal belief and your worry about doing this. One thing about sleep is sleep happens when you are relaxed and calm and not worried. When you're worried about thinking that thing you're worried about is whether or not you're getting sleep, then you don't sleep. In terms of melatonin, if you don't need to use it, I wouldn't use it. If you are gonna use it, I'd try to use as low doses as possible. Do we know all the risks? We don't know. And especially I think there are potentially more risks in a growing child than, maybe someone who isn't having the same sort of hormonal, needs and growth needs. But then again, if you have, let's say, a kid with autism and melatonin helps him sleep, I'd much rather use melatonin than a lot of other agents, and if that really changes their functionality, that probably is very good for them and better than having them not get sleep. So, I think you have to weigh each individual situation and combine it, especially with the behavioral approaches so that hopefully this is not a long-term addictive thing you're on.  Dr Jones: So, it's complicated. Sounds like it.  Dr Albin: Not a straightforward answer.   Dr Jones: I thought that was gonna be just this hard no, but I guess it is something you have to think about. So, I want to really take a minute here to thank Dr. Karin Johnson, who has been our interviewee for this episode of the Continuum Audio Podcast sleep issue just came out. Really want to encourage our subscribers, our listeners, and our studio audience here to enjoy it. Thank you, Dr. Johnson, for joining us today. I want to give a big round of applause to Dr. Casey Albin for managing this crowd. Thank you to our listeners. Thank you to our subscribers. Thank you to you all for coming today.  Dr Monteith: This is Dr. Teshamae Monteith, Associate Editor of Continuum Audio. If you've enjoyed this episode, you'll love the journal, which is full of in-depth and clinically relevant information important for neurology practitioners. Use the link in the episode notes to learn more and subscribe. Thank you for listening to Continuum Audio.   

What if transplant patients could one day live free from lifelong anti-rejection drugs?  In this episode of Mayo Clinic's Tomorrow's Cure, host Lindsey Seavert speaks with Timucin Taner, M.D., Ph.D. from Mayo Clinic and Angus Thomson, Ph.D. from University of Pittsburgh Medical Center about one of the biggest goals in transplant medicine: teaching the immune system to accept a donated organ instead of attacking it. From the liver's unique ability to promote immune tolerance to promising cell therapies and donor-derived treatments, the conversation explores how researchers are working to retrain the immune system, reduce side effects, and improve long-term outcomes for transplant recipients. Along the way, they discuss the future of kidney, heart, and lung transplantation, the promise of xenotransplantation, and how breakthroughs in transplant science may also help advance treatment for autoimmune disease. How to listen and stay connected: Subscribe to Tomorrow's Cure on your favorite podcast app and follow the show so you never miss an episode. Get the latest health information from Mayo Clinic's experts—subscribe to Mayo Clinic's newsletter for free today: https://mayocl.in/3EcNPNc Connect with Mayo Clinic: Like Mayo Clinic on Facebook: https://www.facebook.com/mayoclinic/ Follow Mayo Clinic on Instagram: https://www.instagram.com/mayoclinic/ Follow Mayo Clinic on X (formerly Twitter): https://x.com/MayoClinic Follow Mayo Clinic on Threads: https://www.threads.net/@mayoclinic

August 4, 2026: Your daily rundown of health and wellness news, in under 5 minutes. Today's top stories: Mayo Clinic publishes studies advancing the science of senescent "zombie" cells, identifying new biomarkers of biological aging to build the foundation for targeted longevity therapies Apple reportedly positions future smart glasses as a health and fitness device, hiring a product leader to extend its wearables health strategy beyond the Apple Watch Nike launches Hybrid, a new footwear platform built for hybrid training and racing, signaling long-term investment in fitness's fastest-growing category More from Fitt: Fitt Insider breaks down the convergence of fitness, wellness, and healthcare — and what it means for business, culture, and capital. Subscribe to our newsletter → insider.fitt.co/subscribe Work with our recruiting firm → https://talent.fitt.co/ Follow us on Instagram → https://www.instagram.com/fittinsider/ Follow us on LinkedIn → linkedin.com/company/fittinsider Reach out → insider@fitt.co

Host: Darryl S. Chutka, M.D.  Guest: Josh P. Wiedermann, M.D. Neck masses in children are commonly seen in a primary care practice. Fortunately, most are benign, although serious causes, including malignancy, always remain a possibility. Based on medical history, physical examination, and occasionally imaging studies, the cause is usually able to be identified. What are some key elements consistent with a benign neck mass? When does the management consist of watchful waiting and which ones are concerning and should warrant a prompt referral? These are questions I'll be asking my guest, Dr. Josh Wiedermann, Division Chair of Pediatric Otorhinolaryngology at the Mayo Clinic as we discuss “Pediatric Neck Masses”.  Connect with us! Mayo Clinic Talks Podcast Season 6 | Mayo Clinic School of Continuous Professional Development 

More people are turning to AI chatbots with health questions, and they're getting quick, confident answers. But how much should you actually trust what AI tells you? In this episode, we hear from two doctors about whether AI can really help patients become more informed, and when you definitely still need a human doctor.  You'll hear from both Dr. Matthew Callstrom from Mayo Clinic and Dr. Celine Gounder from CBS News and KFF Health News.   Learn more about our guest(s): https://www.theNewsWorthy.com/shownotes Join us again for our 15-minute daily news roundups every Mon-Fri!  Become an INSIDER and get ad-free episodes here: https://www.theNewsWorthy.com/insider Get The NewsWorthy MERCH here: https://www.theNewsWorthy.com/merch Sponsors: For a limited time, get 60% off your first order, plus free shipping and free treats for life, when you head to Smalls.com/NEWSWORTHY. Search Whatnot—in the App Store, download, and you can sign-up and start selling right away! To advertise on our podcast, please email: ad-sales@libsyn.com

- Anthony Fauci's post-hearing fallout intensifies as critics challenge his pandemic record, media protection and attempts to place government “science” beyond public scrutiny. - Mayo Clinic research on second opinions shows why medical conclusions must remain open to challenge, with most patients receiving a revised, clarified or completely different diagnosis. - Dr. Jeff Barke and Joanne Thomas demand accountability for COVID mandates, censorship and nursing-home isolation after Fauci repeatedly invokes the Fifth Amendment before Congress. - U.S. operations against Iran face heavy political criticism despite flying fewer missions than the Obama administration launches during its intervention in Libya. - Daily marijuana use surpasses cigarette smoking as experts clash over high-potency cannabis, addiction risks and the rapid expansion of THC beverages. Make the switch to NEWSMAX today! Get your 15 day free trial of NEWSMAX+ at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠http://NewsmaxPlus.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Follow NEWSMAX on Social Media:            • Facebook: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠http://nws.mx/FB⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠            • X/Twitter: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠http://nws.mx/twitter⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠            • Instagram: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠http://nws.mx/IG⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠            • YouTube: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://youtube.com/NewsmaxTV⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠            • Rumble: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://rumble.com/c/NewsmaxTV⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠            • TRUTH Social: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://truthsocial.com/@NEWSMAX⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Learn more about your ad choices. Visit megaphone.fm/adchoices

In this episode of the Oncology Brothers podcast we continued our treatment algorithm series, focusing on early relapsed/refractory multiple myeloma (RRMM). We were joined by Dr. Shaji Kumar, a myeloma specialist from the Mayo Clinic, who shared his insights into current evidence-based treatment strategies for patients whose disease has progressed after frontline therapy.   Key topics discussed included: The current standard of care for frontline multiple myeloma, including quadruplet therapy and maintenance strategies The role of CAR T-cell therapy and bispecific antibodies, including teclistamab and talquetamab, in early relapsed/refractory multiple myeloma Treatment selection based on patient age, prior therapy, drug exposure, and disease biology The importance of shared decision-making and incorporating patient preferences into treatment planning Recent clinical trial data and emerging therapies shaping the future of multiple myeloma care This episode provides practical insights into managing early relapsed/refractory disease and navigating today's evolving treatment landscape.   Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o  Follow us on social media: X/Twitter: https://x.com/oncbrothers ⁠Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/    Subscribe for more expert discussions on multiple myeloma, hematologic malignancies, cellular therapies, bispecific antibodies, and precision oncology. #MultipleMyeloma #CART #BispecificAntibodies #Hematology #Oncology

Host: Darryl S. Chutka, M.D.  Guest: Karthik Ravi, M.D.  Eosinophilic Esophagitis is often misdiagnosed or undiagnosed in primary care settings, yet it's a common cause of esophageal symptoms. It's commonly mistaken for the more common gastroesophageal reflux disease as it can present with symptoms of reflux and dysphagia. How can we differentiate eosinophilic esophagitis from reflux esophagitis? What's needed to establish a diagnosis? What are the management options and what's the long-term outlook for those with the condition? These are some of the questions I'll be asking my guest Dr. Karthik Ravi, a gastroenterologist at the Mayo Clinic as we discuss “Eosinophilic Esophagitis”.  Connect with us! Mayo Clinic Talks Podcast Season 6 | Mayo Clinic School of Continuous Professional Development 

You’ve probably heard the words ‘biofeedback' and ‘neurofeedback' floating around the internet. And you're also probably wondering what they mean and if they're worth your time and money when you have a vestibular disorder. I'm answering all of that in this episode! Biofeedback is a type of mind-body technique to control some of the body's function. And neurofeedback is a type of biofeedback that measures and records brainwaves. As always, I've got research and scenarios for us to talk through to help this really land. They're probably not the first thing you want to invest in and there are even less expensive options that are equally or more effective which I share more about in the episode. Buckle up and let's get a little nerdy with this one! In this episode, we'll dig into: What biofeedback is and how it works What the main types of biofeedback are What neurofeedback is and how it relates to biofeedback The difference between active and passive neurofeedback The two main models of biofeedback that exist What to expect in a biofeedback session What biofeedback is considered effective for Types of neurofeedback and biofeedback sessions, devices, and apps available How to find a qualified biofeedback provider What questions to ask before committing to either option If you want to go even deeper with what you heard in this episode, we have coaching calls specifically about biofeedback and neurofeedback available in Vestibular Group Fit. Biofeedback is a tool, not a cure. But if you’re curious, informed, and financially comfortable exploring it, it absolutely can have a place in your vestibular toolkit. Links Mentioned: Vestibular Group Fit (code GROUNDED at checkout for 15% off!): https://thevertigodoctor.com/vestibular-group-fit Certification from the Association for Applied Psychophysiology and Biofeedback (AAPB) site has an option to find a practitioner: https://aapb.org/Find_a_Practitioner  Hearthmath: https://www.heartmath.com/  Resperate (FDA approved for blood pressure and stress): https://resperate.com  Leva (FDA approved for pelvic floor): https://levacares.com/  Prism (FDA approved for PTSD): https://www.graymatters-health.com/prism-for-ptsd  Finding a provider International society for neuroregulation and research: https://isnr.org/ Biofeedback certification international alliance: https://www.bcia.org/ Free Resources: ⁠The 4 Steps to Managing Vestibular Migraine: https://thevertigodoctor.myflodesk.com/cb5js0y78n ⁠The PPPD Management Masterclass⁠: https://thevertigodoctor.myflodesk.com/new-pppd ⁠What your Partner Should Know About Living with Dizziness⁠: https://thevertigodoctor.myflodesk.com/partnership ⁠The FREE Mini VGFit Workout⁠: https://thevertigodoctor.myflodesk.com/minifit ⁠The FREE POTS – safe Workouts⁠: https://thevertigodoctor.myflodesk.com/pots Connect with Dr. Madison (@TheVertigoDoctor): https://instagram.com/thevertigodoctor Work with Dr. Madison: For 1:1 Vestibular Rehabilitation Therapy, email madison@thevertigodoctor.com Otherwise, I'll see ya in Vestibular Group Fit! Connect with Dr. Jenna (@dizzy.rehab.therapist): https://www.instagram.com/dizzy.rehab.therapist/ Learn about the Oak Method: http://thevertigodoctor.com/why-vestibular-group-fit Love what you heard?Consider leaving a review on your favorite podcast platform to help us reach more vestibular warriors like you! This podcast is for informational purposes only and may not be the best fit for you and your personal situation. It shall not be construed as medical advice. The information and education provided here is not intended or implied to supplement or replace professional medical treatment, advice, and/or diagnosis. Always check with your own physician or medical professional before trying or implementing any information read here. Citations Frank, D. L., Khorshid, L., Kiffer, J. F., Moravec, C. S., & McKee, M. G. (2010). Biofeedback in medicine: who, when, why and how?. Mental health in family medicine, 7(2), 85–91. Mayo Clinic. “Biofeedback – Mayo Clinic.” Mayoclinic.org, 18 Mar. 2023, www.mayoclinic.org/tests-procedures/biofeedback/about/pac-20384664. Marzbani, H., Marateb, H. R., & Mansourian, M. (2016). Neurofeedback: A Comprehensive Review on System Design, Methodology and Clinical Applications. Basic and clinical neuroscience, 7(2), 143–158. https://doi.org/10.15412/J.BCN.03070208 Bazzana, F., Finzi, S., Di Fini, G., & Veglia, F. (2022). Infra-Low Frequency Neurofeedback: A Systematic Mixed Studies Review. Frontiers in human neuroscience, 16, 920659. https://doi.org/10.3389/fnhum.2022.920659 Duke, G., Yotter, C. N., Sharifian, B., Duke, G., & Petersen, S. (2024). The effectiveness of microcurrent neurofeedback on depression, anxiety, post-traumatic stress disorder, and quality of life. Journal of the American Association of Nurse Practitioners, 36(2), 100–109. https://doi.org/10.1097/JXX.0000000000000945 Cleveland Clinic. “Biofeedback: What Is It & Procedure Details.” Cleveland Clinic, 21 Dec. 2020, my.clevelandclinic.org/health/treatments/13354-biofeedback. biofeedback and neurofeedback, biofeedback vs neurofeedback, vestibular group fit, VGF, vestibular disorders, chronic dizziness, PPPD, nervous system regulation, migraine management, stress relief, alternative therapies, holistic approach, living with vestibular migraine, living with vertigo, migraine toolkit, vestibular disorder treatment

Like tens of millions of people, Stephen Dubner thought he had a penicillin allergy. Like the vast majority, he didn't. This misdiagnosis costs billions of dollars and causes serious health problems, so why hasn't it been fixed? We find out in this update of a 2025 episode.   SOURCES: Kimberly Blumenthal, allergist-immunologist and researcher at the Mayo Clinic. Theresa MacPhail, associate professor of science and technology studies at Stevens Institute of Technology. Thomas Platts-Mills, professor of medicine at the University of Virginia. Elena Resnick, allergist and immunologist at Mount Sinai Hospital.   RESOURCES: Allergic: Our Irritated Bodies in a Changing World, by Theresa MacPhail (2023). "Evaluation and Management of Penicillin Allergy: A Review," by Erica S. Shenoy, Eric Macy, and Theresa Rowe (JAMA, 2019). "The Allergy Epidemics: 1870–2010," by Thomas Platts-Mills (The Journal of Allergy and Clinical Immunology, 2016). "Randomized Trial of Peanut Consumption in Infants at Risk for Peanut Allergy," by George Du Toit, Graham Roberts, et al. (The New England Journal of Medicine, 2015).   EXTRAS: "The Freakonomics Radio Guide to Getting Better," series by Freakonomics Radio (2026). "Doctors Know They Prescribe Too Many Antibiotics. Why Don't They Stop?" by Freakonomics, M.D. (2022). Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.